Enteroviruses: Polio

Chapter
First Online:

Abstract

Poliomyelitis (polio), the much-feared crippling epidemic disease of the twentieth century, is on the verge of eradication. Before introduction of the inactivated poliovirus vaccine (IPV) in 1955 and the oral poliovirus vaccine (OPV) in 1961, polio had nearly a worldwide distribution, with widespread circulation of all three serotypes of the etiologic agent, poliovirus. Effective immunization programs in developed countries stopped endemic poliovirus circulation by the early 1970s, but circulation continued virtually unabated for many more years in most developing countries, continuing to threaten the majority of the world’s children with lifelong paralysis. As the result of intensive immunization activities launched by the World Health Organization in the Americas in 1985 and worldwide through the Global Polio Eradication Initiative (GPEI) in 1988, polio, like smallpox before it, is becoming a fading memory. Circulation of indigenous wild type 2 poliovirus ceased in 1999, wild type 3 poliovirus was last detected in November 2012, and unbroken circulation wild type 1 poliovirus has continued in parts of only three countries. Polio case counts have declined by >99% worldwide, from an estimated 350,000 cases in 1988 to 223 cases reported in 2012. However, progress has been uneven, with repeated setbacks after 2000 as wild polioviruses from endemic reservoirs reinfected polio-free countries and emerging circulating vaccine derived polioviruses sparked outbreaks in settings of declining population immunity to poliovirus. Nonetheless, the feasibility of global polio eradication has been repeatedly demonstrated in the most challenging settings on earth, including areas of conflict, extreme poverty, crowding, poor hygiene and sanitation, very weak infrastructure, and in environmental conditions favoring intense virus transmission. Eradication of polio in once hyperendemic India in 2011, has set the stage for the final push to global polio eradication.

Polioviruses are members of the Enterovirus genus, comprising >100 serotypes, inhabitants of the intestinal tracts and/or the nasopharyngeal tissues of humans and other mammals. Polioviruses, for which humans are the only natural reservoir host, occasionally invade the central nervous system (CNS) and cause destruction of motor neurons in the spinal cord, resulting in acute flaccid paralysis. However, poliovirus invasion of the CNS occurs in <1% of infections, and represents a dead-end for transmission, which is sustained by the fecal-oral or respiratory routes. The abrupt appearance in the late nineteenth century of large polio outbreaks in Europe and North America generated intense interest in the disease and prompted intensive studies of poliovirus epidemiology, pathology, immunology, and virology, leading to the development and worldwide deployment of effective poliovirus vaccines and many groundbreaking contributions to public health, medical science, and basic research.

The GPEI, the largest public health program in history, has coordinated the vaccination of 2.5 billion children, saving >10 million people (mostly children <2 years of age) from lifelong paralysis and sparing the lives of >250,000 others. The GPEI has trained a new generation of highly experienced health professionals and volunteers who are poised to control many other vaccine-preventable diseases, and has developed a detailed endgame strategic plan to secure forever the many gains achieved by polio eradication.

This is a preview of subscription content, log in to check access.

References

  1. 1.
    Paul JR. A history of poliomyelitis. New Haven: Yale University Press; 1971.Google Scholar
  2. 2.
    Melnick JL. Portraits of viruses: the picornaviruses. Intervirology. 1983;20:61–100.PubMedGoogle Scholar
  3. 3.
    Oshinsky DM. Polio: an American story. New York: Oxford University Press; 2005.Google Scholar
  4. 4.
    Salk JE, Krech U, Youngner JS, Bennett BL, Lewis LJ, Bazeley PL. Formaldehyde treatment and safety testing of experimental poliomyelitis vaccines. Am J Public Health. 1954;44:563–70.Google Scholar
  5. 5.
    Vidor E, Plotkin SA. Poliovirus vaccine—inactivated. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 6th ed. London: W.B. Saunders; 2013. p. 573–97.Google Scholar
  6. 6.
    Sabin AB. Oral poliovirus vaccine: history of its development and use, and current strategies to eliminate poliomyelitis from the world. J Infect Dis. 1985;151:420–36.PubMedGoogle Scholar
  7. 7.
    Sutter RW, Kew OM, Cochi SL, Aylward RB. Poliovirus vaccine—live. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 6th ed. London: W.B. Saunders; 2013. p. 598–645.Google Scholar
  8. 8.
    Cockburn WC, Drozdov SG. Poliomyelitis in the world. Bull World Health Organ. 1970;42:405–17.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Paccaud MF. World trends in poliomyelitis morbidity and mortality, 1951–1975. World Health Stat Q. 1979;32:198–224.PubMedGoogle Scholar
  10. 10.
    Kew O. Reaching the last one per cent: progress and challenges in global polio eradication. Curr Opin Virol. 2012;2:188–98.PubMedGoogle Scholar
  11. 11.
    Kew OM, Pallansch MA. The mechanism of polio eradication. In: Semler BL, Wimmer E, editors. Molecular biology of picornaviruses. Washington, D.C.: ASM Press; 2002. p. 481–91.Google Scholar
  12. 12.
    World Health Organization. Progress towards global interruption of wild poliovirus transmission, January 2012–March 2013. Wkly Epidemiol Rec. 2013;88:181–7.Google Scholar
  13. 13.
    Centers for Disease Control and Prevention. Apparent global interruption of wild poliovirus type 2 transmission. MMWR Morb Mortal Wkly Rep. 2001;50:222–4.Google Scholar
  14. 14.
    Pan American Health Organization. Director announces campaign to eradicate poliomyelitis from the Americas by 1990. Bull Pan Am Health Organ. 1985;19:21–35.Google Scholar
  15. 15.
    World Health Assembly. Polio eradication by the year 2000. Geneva: World Health Organization; 1988.Google Scholar
  16. 16.
    World Health Organization. Progress towards interrupting wild poliovirus transmission worldwide: January 2010–March 2011. Wkly Epidemiol Rec. 2011;86:199–204.Google Scholar
  17. 17.
    Pigman HA. Conquering polio. Evanston: Rotary International; 2005.Google Scholar
  18. 18.
    de Quadros CA, Andrus JK, Olivé JM, Guerra de Macedo C, Henderson DA. Polio eradication from the Western Hemisphere. Ann Rev Public Health. 1992;13:239–52.Google Scholar
  19. 19.
    Aylward B, Yamada T. The polio endgame. N Engl J Med. 2011;364:2273–5.PubMedGoogle Scholar
  20. 20.
    Arita I, Francis DP. Safe landing for global polio eradication: a perspective. Vaccine. 2011;29:8827–34.PubMedGoogle Scholar
  21. 21.
    Donaldson L, Toole M, El Sayed N, et al. Polio’s last stand? Sixth report of the Independent Monitoring Board of the Global Polio Eradication Initiative, November 2012. (http://www.polioeradication.org/imb.aspx)2012.
  22. 22.
  23. 23.
    Melnick JL. Poliovirus and other enteroviruses. In: Evans AS, Kaslow RA, editors. Viral infections of humans, epidemiology and control. 4th ed. New York: Plenum; 1997. p. 583–663.Google Scholar
  24. 24.
    Brown B, Oberste MS, Maher K, Pallansch M. Complete genomic sequencing shows that polioviruses and members of human enterovirus species C are closely related in the non-capsid coding region. J Virol. 2003;77:8973–84.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Knowles NJ, Hovi T, Hyypiä T, et al. Picornaviridae. In: King AMQ, Adams MJ, Carstens EB, Lefkowitz EJ, editors. Virus taxonomy: classification and nomenclature of viruses: ninth report of the International Committee on Taxonomy of Viruses. San Diego: Elsevier; 2011. p. 855–80.Google Scholar
  26. 26.
    Mueller S, Wimmer E, Cello J. Poliovirus and poliomyelitis: a tale of guts, brains, and an accidental event. Virus Res. 2005;111:175–93.PubMedGoogle Scholar
  27. 27.
    Ehrenfeld E, Domingo E, Roos R, editors. The picornaviruses. Washington, D.C.: ASM Press; 2010.Google Scholar
  28. 28.
    Paul JR. Epidemiology of poliomyelitis. In: Poliomyelitis, vol. World Health Organization monograph series no. 26. Geneva: World Health Organization; 1955. p. 9–29.Google Scholar
  29. 29.
    Bodian D, Horstmann DM. Polioviruses. In: Horsfall Jr FL, Tamm I, editors. Viral and rickettsial infections of man. 4th ed. Philadelphia: J.B. Lippincott; 1965. p. 430–73.Google Scholar
  30. 30.
    Dowdle WR, Cochi SL. Global eradication of poliovirus: history and rationale. In: Semler BL, Wimmer E, editors. Molecular biology of picornaviruses. Washington, D.C.: ASM Press; 2002. p. 473–80.Google Scholar
  31. 31.
    Eggers HJ. History of poliomyelitis and poliomyelitis research. In: Semler BL, Wimmer E, editors. Molecular biology of picornaviruses. Washington, D.C.: American Society for Microbiology; 2002. p. 3–14.Google Scholar
  32. 32.
    Robbins FC. The history of polio vaccine development. In: Plotkin SA, Orenstein WA, editors. Vaccines. 4th ed. Philadelphia: W.B. Saunders Company; 2004. p. 17–30.Google Scholar
  33. 33.
    Smallman-Raynor MR, Cliff AD. Poliomyelitis: a world geography: emergence to eradication. New York: Oxford University Press; 2006.Google Scholar
  34. 34.
    Nathanson N, Kew OM. From emergence to eradication: the epidemiology of poliomyelitis deconstructed. Am J Epidemiol. 2010;172:1213–29.PubMedPubMedCentralGoogle Scholar
  35. 35.
    Plotkin SL, Plotkin SA. A short history of vaccination. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 6th ed. London: W.B. Saunders; 2013. p. 1–13.Google Scholar
  36. 36.
    Underwood M. A treatise on the diseases of children. London: J. Mathews; 1789.Google Scholar
  37. 37.
    Heine J. Spinale Kinderlähmung, 2. umgearbeitete und vermehrte Auflage. Stuttgart: J.G. Cotta’scher Verlag; 1860.Google Scholar
  38. 38.
    Medin O. Über eine Epidemie von spinaler Kindelähmung. Verhandl. d. 10. Internat Med Kongr. Berlin;1891. p.37–47.Google Scholar
  39. 39.
    Trevelyan B, Smallman-Raynor M, Cliff AD. The spatial dynamics of poliomyelitis in the United States: from epidemic emergence to vaccine-induced retreat, 1910–1971. Ann Assoc Am Geogr. 2005;95:269–93.PubMedPubMedCentralGoogle Scholar
  40. 40.
    Caverly CS. Notes of an epidemic of acute anterior poliomyelitis. J Am Med Assoc. 1896;26:1–5.Google Scholar
  41. 41.
    Wickman I. Die akute Poliomyelitis bzw. Heine-Medinsche Krankheit. Berlin: Julius Springer; 1911.Google Scholar
  42. 42.
    Landsteiner K, Popper E. Übertragung der Poliomyelitis acuta auf Affen. Z Immunitätsforsch exp Ther. 1909;2:377–90.Google Scholar
  43. 43.
    Flexner S, Lewis PA. The transmission of epidemic poliomyelitis to monkeys: a further note. J Am Med Assoc. 1909;53:1913.Google Scholar
  44. 44.
    Kling C, Petterson A, Wernstedt W. Experimental and pathological investigation. I. The presence of the microbe of infantile paralysis in human beings (Trans: Rosen AV). Commun State Med Inst. 1912;3:12.Google Scholar
  45. 45.
    Lavinder CH, Freeman AW, Frost WH. Epidemiologic studies of poliomyelitis in New York City and the northeastern United States during the year 1916. Public Health Bulletin No 91. Washington, D.C: Government Printing Office; 1918.Google Scholar
  46. 46.
    United States Public Health and Marine-Hospital Service. Poliomyelitis in the United States. Public Health Rep. 1910;25:1347–50.Google Scholar
  47. 47.
    Drinker P, Shaw LA. An apparatus for the prolonged administration of artificial respiration: I. A design for adults and children. J Clin Invest. 1929;7:229–47.PubMedPubMedCentralGoogle Scholar
  48. 48.
    Burnet FM, Macnamara J. Immunological differences between strains of poliomyelitic virus. Br J Exp Pathol. 1931;12:57–61.PubMedCentralGoogle Scholar
  49. 49.
    Armstrong C. Successful transfer of Lansing strain of poliomyelitis virus from the cotton rat to the white mouse. Public Health Rep. 1939;54:2302–5.Google Scholar
  50. 50.
    Trask JD, Paul JR, Vignec AJ. I. Poliomyelitic virus in human stools. J Exp Med. 1940;71:751–63.PubMedPubMedCentralGoogle Scholar
  51. 51.
    Trask JD, Paul JR. Periodic examination of sewage for the virus of poliomyelitis. J Exp Med. 1942;75:1–6.PubMedPubMedCentralGoogle Scholar
  52. 52.
    Sabin AB, Ward R. The natural history of human poliomyelitis. I. Distribution of virus in nervous and non-nervous tissues. J Exp Med. 1941;73:771–93.PubMedPubMedCentralGoogle Scholar
  53. 53.
    Enders J, Weller T, Robbins F. Cultivation of the Lansing strain of poliomyelitis virus in cultures of various human embryonic tissues. Science. 1949;109:85–7.PubMedGoogle Scholar
  54. 54.
    Bodian D, Morgan IM, Howe HA. Differentiation of types of poliomyelitis viruses. III. The grouping of fourteen strains into three basic immunologic types. Am J Hyg. 1949;49:234–45.PubMedGoogle Scholar
  55. 55.
    Committee on Typing of the National Foundation for Infantile Paralysis. Immunologic classification of poliomyelitis viruses: a cooperative program for the typing of one hundred strains. Am J Hyg. 1951;54:191–204.Google Scholar
  56. 56.
    Serfling RE, Sherman IL. Poliomyelitis distribution in the United States. Public Health Rep. 1953;68:943–55.Google Scholar
  57. 57.
    Hammon WM, Coriell LL, Wehrle PF, Stokes Jr J. Evaluation of Red Cross gamma globulin as a prophylactic agent for poliomyelitis. IV. Final report of results based on clinical diagnoses. J Am Med Assoc. 1953;151:1272–85.PubMedGoogle Scholar
  58. 58.
    Horstmann DM, McCollum RW, Mascola AD. Viremia in human poliomyelitis. J Exp Med. 1954;99:355–69.PubMedPubMedCentralGoogle Scholar
  59. 59.
    Francis Jr T, Korns RF, Voight RB, et al. An evaluation of the 1954 poliomyelitis vaccine trials. Am J Public Health. 1955;45:1–63.Google Scholar
  60. 60.
    Chumakov MP, Voroshilova MK, Drozdov SG, et al. Some results of the work on mass immunization in the Soviet Union with live poliovirus vaccine prepared from Sabin strains. Bull World Health Organ. 1961;25:79–91.PubMedPubMedCentralGoogle Scholar
  61. 61.
    United States Public Health Service. Public Health Rep 1910–1951.Google Scholar
  62. 62.
    Dauer CC. National morbidity reporting–revised system. Public Health Rep. 1952;67:21–5.PubMedPubMedCentralGoogle Scholar
  63. 63.
    Centers for Disease Control and Prevention. Morbid Mortal Wkly Rep. 1952–1972.Google Scholar
  64. 64.
    Centers for Disease Control and Prevention. Annual poliomyelitis surveillance summaries for years 1960–1973. Atlanta 1961–1974.Google Scholar
  65. 65.
    International Symposium on Poliomyelitis Control. Poliomyelitis: papers and discussions presented at the First through Fifth International Poliomyelitis Conferences. Philadelphia: Lippincott; 1949, 1952, 1955, 1958, 1961.Google Scholar
  66. 66.
    Freyche M-J, Nielsen J. Incidence of poliomyelitis since 1920. In: Poliomyelitis, vol. World Health Organization monograph series no. 26. Geneva: World Health Organization; 1955. p. 59–106.Google Scholar
  67. 67.
    World Health Organization. Poliomyelitis surveillance. Wkly Epidemiol Rec. 1970;45:189–94.Google Scholar
  68. 68.
    Andrus JK, de Quadros C, Olivé JM, Hull HF. Screening of cases of acute flaccid paralysis for poliomyelitis eradication: ways to improve specificity. Bull World Health Organ. 1992;70:591–6.PubMedPubMedCentralGoogle Scholar
  69. 69.
    Pinheiro FP, Kew O, Hatch MH, Silveira CM, de Quadros CA. Eradication of wild polioviruses from the Americas. Part II. Wild poliovirus surveillance: laboratory issues. J Clin Microbiol. 1997;175 Suppl 1:S43–9.Google Scholar
  70. 70.
    Pan American Health Organization. EPI Newsl. 1985–1994;7(3)–16(4).Google Scholar
  71. 71.
    World Health Organization. Wkly Epidemiol Rec. 1985–.Google Scholar
  72. 72.
    Centers for Disease Control and Prevention. Morbid Mortal Wkly Rep. 1985–.Google Scholar
  73. 73.
    United States Public Health Service. Poliomyelitis (infantile paralysis)—the accuracy of diagnosis under epidemic conditions. Public Health Rep. 1916;31:3291.Google Scholar
  74. 74.
    Birmingham ME, Linkins RW, Hull BP, Hull HF. Poliomyelitis surveillance: the compass for eradication. J Infect Dis. 1997;175 Suppl 1:S146–50.PubMedGoogle Scholar
  75. 75.
    de Quadros CA, Hersh BS, Olive JM, Andrus JK, da Silveira CM, Carrasco PA. Eradication of wild poliovirus from the Americas: acute flaccid paralysis surveillance, 1988–1995. J Infect Dis. 1997;175 Suppl 1:S37–42.PubMedGoogle Scholar
  76. 76.
    Sabin AB. Paralytic consequences of poliomyelitis infection in different parts of the world and in different population groups. Am J Public Health. 1951;41:1215–30.Google Scholar
  77. 77.
    Doshi SJ, Sandhu HS, Venczel LV, et al. Poliomyelitis-related case-fatality ratio in India, 2002–2006. Clin Infect Dis. 2011;53:13–9.PubMedGoogle Scholar
  78. 78.
    Prevots DR, Ciofi degli Atti ML, Sallabanda A, et al. Outbreak of paralytic poliomyelitis in Albania, 1996: high attack rate among adults and apparent interruption of transmission following nationwide mass vaccination. Clin Infect Dis. 1998;26:419–25.PubMedGoogle Scholar
  79. 79.
    World Health Organization. Outbreak of poliomyelitis, Cape Verde: August–October 2000. Wkly Epidemiol Rec. 2000;75:401.Google Scholar
  80. 80.
    World Health Organization. Outbreak of type-1 wild poliovirus in adults, Namibia, 2006. Wkly Epidemiol Rec. 2006;81:425–30.Google Scholar
  81. 81.
    Patel MK, Konde MK, Didi-Ngossaki BH, et al. An outbreak of wild poliovirus in the Republic of Congo, 2010-2011. Clin Infect Dis. 2012;55:1291–8.PubMedGoogle Scholar
  82. 82.
    World Health Organization. Progress towards global interruption of wild poliovirus transmission, January 2011–March 2012. Wkly Epidemiol Rec. 2012;87:195–200.Google Scholar
  83. 83.
    Paul JR. Development and use of serum surveys. In: Paul JR, White C, editors. Serological epidemiology. New York: Academic Press; 1973. p. 1–13.Google Scholar
  84. 84.
    Aycock WL, Kramer SD. Immunity to poliomyelitis in normal individuals in urban and rural communities as indicated by the neutralization test. J Prev Med. 1930;4:189–200.Google Scholar
  85. 85.
    Paul JR, Riordan JT, Melnick JL. Antibodies to three different antigenic types to poliomyelitis virus in sera from North Alaskan Eskimos. Am J Hyg. 1951;54:275–85.PubMedGoogle Scholar
  86. 86.
    Melnick JL, Ledinko N. Development of neutralizing antibodies against the three types of poliomyelitis virus during an epidemic period. The ratio of inapparent infection to clinical poliomyelitis. Am J Hyg. 1953;58:207–22.PubMedGoogle Scholar
  87. 87.
    Poland JD, Plexico K, Flynt JW, Chin TD. Poliovirus neutralizing antibody levels among preschool children. Public Health Rep. 1968;83:507–12.PubMedPubMedCentralGoogle Scholar
  88. 88.
    Melnick JL. Periodic serological surveillance. In: Paul JR, White C, editors. Serological surveillance. New York: Academic Press; 1973. p. 143–54.Google Scholar
  89. 89.
    Sutter RW, Patriarca PA, Brogan S, et al. An outbreak of paralytic poliomyelitis in Oman: evidence for widespread transmission among fully vaccinated children. Lancet. 1991;338:715–20.PubMedGoogle Scholar
  90. 90.
    Patriarca PA, Wright PF, John TJ. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis. 1991;13:926–39.PubMedGoogle Scholar
  91. 91.
    World Health Organization. Progress towards eradicating poliomyelitis: India, January 2010–September 2011. Wkly Epidemiol Rec. 2011;86:501–7.Google Scholar
  92. 92.
    Sutter RW, John TJ, Jain H, et al. Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial. Lancet. 2010;376:1682–8.PubMedGoogle Scholar
  93. 93.
    Aylward RB, Porta D, Fiore L, Ridolfi B, Chierchini P, Forastiere F. Unimmunized Gypsy populations and implications for the eradication of poliomyelitis in Europe. J Infect Dis. 1997;175 Suppl 1:S86–8.PubMedGoogle Scholar
  94. 94.
    Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol. 2005;59:587–635.PubMedGoogle Scholar
  95. 95.
    El-Sayed N, Al-Jorf S, Hennessey KA, et al. Survey of poliovirus antibodies during the final stage of polio eradication in Egypt. Vaccine. 2007;25:5062–70.PubMedGoogle Scholar
  96. 96.
    Habib M, Soofi S, Ali N, et al. A study evaluating poliovirus antibodies and risk factors associated with polio seropositivity in low socioeconomic areas of Pakistan. Vaccine. 2013;31:1987–93.PubMedGoogle Scholar
  97. 97.
    Bernier RH. Some observations on poliomyelitis lameness surveys. Rev Infect Dis. 1984;6 Suppl 2:S371–5.PubMedGoogle Scholar
  98. 98.
    Ofosu-Amaah S. The challenge of poliomyelitis in tropical Africa. Rev Infect Dis. 1984;6 Suppl 2:S318–20.PubMedGoogle Scholar
  99. 99.
    Basu R, Sokhey J. Prevalence of poliomyelitis in India. Indian J Pediatr. 1984;51:515–9.PubMedGoogle Scholar
  100. 100.
    World Health Organization. Field guide for supplementary activities aimed at achieving polio eradication, 1996 revision. Geneva: World Health Organization; 1997.Google Scholar
  101. 101.
    Nathanson N, Martin JR. The epidemiology of poliomyelitis: enigmas surrounding its appearance, epidemicity, and disappearance. Am J Epidemiol. 1979;110:672–92.PubMedGoogle Scholar
  102. 102.
    Hull HF, Ward NA, Milstien JB, de Quadros C. Paralytic poliomyelitis: seasoned strategies, disappearing disease. Lancet. 1994;343:1331–7.PubMedGoogle Scholar
  103. 103.
    Melnick JL. Poliomyelitis virus in urban sewage in epidemic and in nonepidemic times. Am J Hyg. 1947;45:240–53.PubMedGoogle Scholar
  104. 104.
    Pöyry T, Stenvik M, Hovi T. Viruses in sewage waters during and after a poliomyelitis outbreak and subsequent nationwide oral poliovirus vaccination campaign in Finland. Appl Environ Microbiol. 1988;54:371–4.PubMedPubMedCentralGoogle Scholar
  105. 105.
    Böttiger M, Herrstrom E. Isolation of polioviruses from sewage and their characteristics: experience over two decades in Sweden. Scand J Infect Dis. 1992;24:151–5.PubMedGoogle Scholar
  106. 106.
    van der Avoort HG, Reimerink JH, Ras A, Mulders MN, van Loon AM. Isolation of epidemic poliovirus from sewage during the 1992–3 type 3 outbreak in The Netherlands. Epidemiol Infect. 1995;114:481–91.PubMedPubMedCentralGoogle Scholar
  107. 107.
    Manor Y, Handsher R, Halmut T, et al. Detection of poliovirus circulation by environmental surveillance in the absence of clinical cases in Israel and the Palestinian Authority. J Clin Microbiol. 1999;37:1670–5.PubMedPubMedCentralGoogle Scholar
  108. 108.
    World Health Organization. Tracking progress towards global polio eradication, 2010–2011. Wkly Epidemiol Rec. 2012;87:153–60.Google Scholar
  109. 109.
    Yoshida H, Horie H, Matsuura K, Kitamura T, Hashizume S, Miyamura T. Prevalence of vaccine-derived polioviruses in the environment. J Gen Virol. 2002;83:1107–11.PubMedGoogle Scholar
  110. 110.
    Hovi T, Cantell K, Huovalainen A, Kinnunen E. Outbreak of paralytic poliomyelitis in Finland: widespread circulation of antigenically altered poliovirus type 3 in a vaccinated population. Lancet. 1986;1:1427–32.PubMedGoogle Scholar
  111. 111.
    Tambini G, Andrus JK, Marques E, et al. Direct detection of wild poliovirus transmission by stool surveys of healthy children and analysis of community wastewater. J Infect Dis. 1993;168:1510–4.PubMedGoogle Scholar
  112. 112.
    Robbins FC, de Quadros CA. Certification of the eradication of indigenous transmission of wild poliovirus in the Americas. J Infect Dis. 1997;175 Suppl 1:S281–5.PubMedGoogle Scholar
  113. 113.
    El Bassioni L, Barakat I, Nasr E, et al. Prolonged detection of indigenous wild polioviruses in sewage from communities in Egypt. Am J Epidemiol. 2003;158:807–15.PubMedGoogle Scholar
  114. 114.
    Centers for Disease Control and Prevention. Progress towards poliomyelitis eradication—Egypt, 2003–2004. MMWR Morb Mortal Wkly Rep. 2004;53:820–2.Google Scholar
  115. 115.
    Hovi T, Blomqvist S, Nasr E, et al. Environmental surveillance of wild poliovirus circulation in Egypt–balancing between detection sensitivity and workload. J Virol Methods. 2005;126:127–34.PubMedGoogle Scholar
  116. 116.
    Deshpande JM, Shetty SJ, Siddiqui ZA. Environmental surveillance system to track wild poliovirus transmission. Appl Environ Microbiol. 2003;69:2919–27.PubMedPubMedCentralGoogle Scholar
  117. 117.
    Shulman LM, Manor Y, Sofer D, et al. Neurovirulent vaccine-derived polioviruses in sewage from highly immune populations. PLoS One. 2006;1:e69.PubMedPubMedCentralGoogle Scholar
  118. 118.
    Blomqvist S, Savolainen C, Laine P, et al. Characterization of a highly evolved vaccine-derived poliovirus type 3 isolated from sewage in Estonia. J Virol. 2004;78:4876–83.PubMedPubMedCentralGoogle Scholar
  119. 119.
    Cernáková B, Sobotová Z, Rovný I, Bláhova S, Roivainen M, Hovi T. Isolation of vaccine-derived polioviruses in the Slovak Republic. Eur J Clin Microbiol Infect Dis. 2005;24:438–9.PubMedGoogle Scholar
  120. 120.
    Roivainen M, Blomqvist S, Al-Hello H, et al. Highly divergent neurovirulent vaccine-derived polioviruses of all three serotypes are recurrently detected in Finnish sewage. Euro Surveill. 2010;15:pii/19566.PubMedGoogle Scholar
  121. 121.
    Más Lago P, Gary Jr HE, Pérez LS, et al. Poliovirus detection in wastewater and stools following an immunization campaign in Havana, Cuba. Int J Epidemiol. 2003;32:772–7.PubMedGoogle Scholar
  122. 122.
    Huang QS, Greening G, Baker MG, et al. Persistence of oral polio vaccine virus after its removal from the immunisation schedule in New Zealand. Lancet. 2005;366:394–6.PubMedGoogle Scholar
  123. 123.
    Hull BP, Dowdle WR. Poliovirus surveillance: building the Global Polio Laboratory Network. J Infect Dis. 1997;175 Suppl 1:S113–6.PubMedGoogle Scholar
  124. 124.
    World Health Organization. Polio laboratory manual. 4th ed. Geneva: World Health Organization; 2004.Google Scholar
  125. 125.
    Melnick JL, Wenner HA, Phillips CA. Enteroviruses. In: Lennette EH, Schmidt NJ, editors. Diagnostic procedures for viral, rickettsial, and chlamydial infections. Washington, D.C.: American Public Health Association; 1979. p. 471–534.Google Scholar
  126. 126.
    Pallansch MA, Oberste MS. Enteroviruses and parechoviruses. In: Specter S, Hodinka RL, Young SA, Wiedbrauk DL, editors. Clinical virology manual. 4th ed. Washington, D.C.: ASM Press; 2009. p. 249–82.Google Scholar
  127. 127.
    World Health Organization. Polio Laboratory Network Quarterly Update 1995–2007.Google Scholar
  128. 128.
    World Health Organization. Informal consultation of the Global Polio Laboratory Network—June 2008. Wkly Epidemiol Rec. 2008;83:261–8.Google Scholar
  129. 129.
    Featherstone DA, Rota PA, Icenogle J, et al. Expansion of the global measles and rubella laboratory network 2005-09. J Infect Dis. 2011;204 Suppl 1:S491–8.PubMedGoogle Scholar
  130. 130.
    Centers for Disease Control and Prevention. Expanding poliomyelitis and measles surveillance networks to establish surveillance for acute meningitis and encephalitis syndromes—Bangladesh, China, and India, 2006–2008. MMWR Morb Mortal Wkly Rep. 2013;61:1008–11.Google Scholar
  131. 131.
    Centers for Disease Control and Prevention. Building laboratory capacity to support the Global Rotavirus Surveillance Network. MMWR Morb Mortal Wkly Rep. 2013;62:409–12.Google Scholar
  132. 132.
    Alexander JP, Ehresmann K, Seward J, et al. Transmission of imported vaccine-derived poliovirus in an under-vaccinated community—Minnesota, USA. J Infect Dis. 2009;199:391–7.PubMedGoogle Scholar
  133. 133.
    Centers for Disease Control and Prevention. Update on vaccine-derived polioviruses—worldwide, April 2011–June 2012. MMWR Morb Mortal Wkly Rep. 2012;61:741–6.Google Scholar
  134. 134.
    Gary Jr HE, Sanders R, Pallansch MA. A theoretical framework for evaluating the sensitivity of surveillance for detecting wild poliovirus: I. Factors affecting detection sensitivity in a person with acute flaccid paralysis. J Infect Dis. 1997;175 Suppl 1:S135–40.PubMedGoogle Scholar
  135. 135.
    Nolan JP, Wilmer BH, Melnick JL. Poliomyelitis: its highly invasive nature and narrow stream of infection in a community of high socioeconomic level. N Engl J Med. 1955;253:945–54.PubMedGoogle Scholar
  136. 136.
    McAllister RM, Mclnyk J, Finklestein JZ, Adams ECJ, Gardner MB. Cultivation in vitro of cells derived from a human rhabdomyosarcoma. Cancer. 1969;24:520–6.PubMedGoogle Scholar
  137. 137.
    Wood DJ, Hull B. L20B cells simplify culture of polioviruses from clinical samples. J Med Virol. 1999;58:188–92.PubMedGoogle Scholar
  138. 138.
    Nadkarni SS, Deshpande JM. Recombinant murine L20B cell line supports multiplication of group A coxsackieviruses. J Med Virol. 2003;70:81–5.PubMedGoogle Scholar
  139. 139.
    Nakano JH, Hatch MH, Thieme ML, Nottay B. Parameters for differentiating vaccine-derived and wild poliovirus strains. Prog Med Virol. 1978;24:78–206.Google Scholar
  140. 140.
    Crainic R, Couillin P, Blondel B, Cabau N, Boué A, Horodniceanu F. Natural variation of poliovirus neutralization epitopes. Infect Immun. 1983;41:1217–25.PubMedPubMedCentralGoogle Scholar
  141. 141.
    Minor PD, John A, Ferguson M, Icenogle JP. Antigenic and molecular evolution of the vaccine strain of type 3 poliovirus during the period of excretion by a primary vaccinee. J Gen Virol. 1986;67:693–706.PubMedGoogle Scholar
  142. 142.
    Osterhaus ADME, van Wezel AL, Hazendonk TG, UytdeHaag FG, van Asten JA, van Steenis B. Monoclonal antibodies to polioviruses. Comparison of intratypic strain differentiation of poliovirus type 1 using monoclonal antibodies versus cross-absorbed antisera. Intervirology. 1983;20:129–36.PubMedGoogle Scholar
  143. 143.
    van Wezel AL, Hazendonk AG. Intratypic serodifferentiation of poliomyelitis virus by strain-specific antisera. Intervirology. 1979;11:2–8.PubMedGoogle Scholar
  144. 144.
    Nomoto A, Omata T, Toyoda H, et al. Complete nucleotide sequence of the attenuated poliovirus Sabin 1 strain genome. Proc Natl Acad Sci U S A. 1982;79:5793–7.PubMedPubMedCentralGoogle Scholar
  145. 145.
    van der Avoort HGAM, Hull BP, Hovi T, et al. A comparative study of five methods of intratypic differentiation of polioviruses. J Clin Microbiol. 1995;33:2562–6.PubMedPubMedCentralGoogle Scholar
  146. 146.
    Ferguson M, Magrath DI, Minor PD, Schild GC. WHO collaborative study on the use of monoclonal antibodies for the intratypic differentiation of poliovirus strains. Bull World Health Organ. 1986;64:239–46.PubMedPubMedCentralGoogle Scholar
  147. 147.
    Nottay BK, Kew OM, Hatch MH, Heyward JT, Obijeski JF. Molecular variation of type 1 vaccine-related and wild polioviruses during replication in humans. Virology. 1981;108:405–23.PubMedGoogle Scholar
  148. 148.
    Minor PD. Characterization of strains of type 3 poliovirus by oligonucleotide mapping. J Gen Virol. 1982;59:307–17.PubMedGoogle Scholar
  149. 149.
    De L, Nottay BK, Yang C-F, Holloway BP, Pallansch MA, Kew O. Identification of vaccine-related polioviruses by hybridization with specific RNA probes. J Clin Microbiol. 1995;33:562–71.PubMedPubMedCentralGoogle Scholar
  150. 150.
    De L, Yang C-F, da Silva E, et al. Genotype-specific RNA probes for the direct identification of wild polioviruses by blot hybridization. J Clin Microbiol. 1997;35:2834–40.PubMedPubMedCentralGoogle Scholar
  151. 151.
    Yang C-F, De L, Holloway BP, Pallansch MA, Kew OM. Detection and identification of vaccine-related polioviruses by the polymerase chain reaction. Virus Res. 1991;20:159–79.PubMedGoogle Scholar
  152. 152.
    Yang C-F, De L, Yang S-J, et al. Genotype-specific in vitro amplification of sequences of the wild type 3 polioviruses from Mexico and Guatemala. Virus Res. 1992;24:277–96.PubMedGoogle Scholar
  153. 153.
    Kilpatrick DR, Yang C-F, Ching K, et al. Rapid group-, serotype-, and vaccine strain-specific identification of poliovirus isolates by real-time reverse transcription-PCR using degenerate primers and probes containing deoxyinosine residues. J Clin Microbiol. 2009;47:1939–41.PubMedPubMedCentralGoogle Scholar
  154. 154.
    Balanant J, Guillot S, Candréa A, Delpeyroux F, Crainic R. The natural genomic variability of poliovirus analyzed by a restriction fragment polymorphism assay. Virology. 1991;184:645–54.PubMedGoogle Scholar
  155. 155.
    Cherkasova E, Laassri M, Chizhikov V, et al. Microarray analysis of evolution of RNA viruses: evidence of circulation of virulent highly divergent vaccine-derived polioviruses. Proc Natl Acad Sci U S A. 2003;100:9398–403.PubMedPubMedCentralGoogle Scholar
  156. 156.
    Korotkova EA, Park R, Cherkasova EA, et al. Retrospective analysis of a local cessation of vaccination against poliomyelitis: a possible scenario for the future. J Virol. 2003;77:12460–5.PubMedPubMedCentralGoogle Scholar
  157. 157.
    Kilpatrick DR, Nottay B, Yang C-F, et al. Group-specific identification of polioviruses by PCR using primers containing mixed-base or deoxyinosine residues at positions of codon degeneracy. J Clin Microbiol. 1996;34:2990–6.PubMedPubMedCentralGoogle Scholar
  158. 158.
    Kilpatrick DR, Nottay B, Yang C-F, et al. Serotype-specific identification of polioviruses by PCR using primers containing mixed-base or deoxyinosine residues at positions of codon degeneracy. J Clin Microbiol. 1998;36:352–7.PubMedPubMedCentralGoogle Scholar
  159. 159.
    Kilpatrick DR, Ching K, Iber J, et al. Identification of vaccine-derived polioviruses using dual-stage real-time RT-PCR. J Virol Meth. 2014;197:25–8.Google Scholar
  160. 160.
    Centers for Disease Control and Prevention. Laboratory surveillance for wild and vaccine-derived polioviruses—worldwide, January 2008–June 2009. MMWR Morb Mortal Wkly Rep. 2009;58:950–4.Google Scholar
  161. 161.
    Kilpatrick DR, Ching K, Iber J, et al. Multiplex PCR method for identifying recombinant vaccine-related polioviruses. J Clin Microbiol. 2004;42:4313–5.PubMedPubMedCentralGoogle Scholar
  162. 162.
    Minor PD. Antigenic structure of picornaviruses. Curr Top Microbiol Immunol. 1990;161:121–54.PubMedGoogle Scholar
  163. 163.
    Rico-Hesse R, Pallansch MA, Nottay BK, Kew OM. Geographic distribution of wild poliovirus type 1 genotypes. Virology. 1987;160:311–22.PubMedGoogle Scholar
  164. 164.
    Jorba J, Campagnoli R, De L, Kew O. Calibration of multiple poliovirus molecular clocks covering an extended evolutionary range. J Virol. 2008;82:4429–40.PubMedPubMedCentralGoogle Scholar
  165. 165.
    Martín J, Dunn G, Hull R, Patel V, Minor PD. Evolution of the Sabin strain of type 3 poliovirus in an immunodeficient patient during the entire 637-day period of virus excretion. J Virol. 2000;74:3001–10.PubMedPubMedCentralGoogle Scholar
  166. 166.
    Kew OM, Morris-Glasgow V, Landaverde M, et al. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science. 2002;296:356–9.PubMedGoogle Scholar
  167. 167.
    Jegouic S, Joffret M-L, Blanchard C, et al. Recombination between polioviruses and co-circulating Coxsackie A viruses: role in the emergence of pathogenic vaccine-derived polioviruses. PLoS Pathog. 2009;5:e1000412.PubMedPubMedCentralGoogle Scholar
  168. 168.
    Burns C, Shaw J, Jorba J, et al. Multiple independent emergences of type 2 vaccine-derived polioviruses during a large outbreak in northern Nigeria. J Virol. 2013;87:4907–22.PubMedPubMedCentralGoogle Scholar
  169. 169.
    Manor Y, Handsher R, Halmut T, et al. A double-selective tissue culture system for isolation of wild-type poliovirus from sewage applied in a long-term environmental surveillance. Appl Environ Microbiol. 1999;65:94–7.Google Scholar
  170. 170.
    Kew OM, Mulders MN, Lipskaya GY, da Silva EE, Pallansch MA. Molecular epidemiology of polioviruses. Semin Virol. 1995;6:401–14.Google Scholar
  171. 171.
    Gavrilin GV, Cherkasova EA, Lipskaya GY, Kew OM, Agol VI. Evolution of circulating wild poliovirus and of vaccine-derived poliovirus in an immunodeficient patient: a unifying model. J Virol. 2000;74:7381–90.PubMedPubMedCentralGoogle Scholar
  172. 172.
    Liu H-M, Zheng D-P, Zhang L-B, Oberste MS, Pallansch MA, Kew OM. Molecular evolution of a type 1 wild-vaccine poliovirus recombinant during widespread circulation in China. J Virol. 2000;74:11153–61.PubMedPubMedCentralGoogle Scholar
  173. 173.
    Yang C-F, Chen H-Y, Jorba J, et al. Intratypic recombination among lineages of type 1 vaccine-derived poliovirus emerging during chronic infection of an immunodeficient patient. J Virol. 2005;79:12623–34.PubMedPubMedCentralGoogle Scholar
  174. 174.
    Odoom JK, Yunus Z, Dunn G, Minor PD, Martín J. Changes in population dynamics during long-term evolution of Sabin type 1 poliovirus in an immunodeficient patient. J Virol. 2008;82:9179–90.PubMedPubMedCentralGoogle Scholar
  175. 175.
    Centers for Disease Control and Prevention. Wild poliovirus importations—West and Central Africa, January 2003–March 2004. MMWR Morb Mortal Wkly Rep. 2004;53:433–5.Google Scholar
  176. 176.
    Centers for Disease Control and Prevention. Resurgence of wild poliovirus type 1 transmission and consequences of importation—21 countries, 2002–2005. MMWR Morb Mortal Wkly Rep. 2006;55:145–50.Google Scholar
  177. 177.
    Centers for Disease Control and Prevention. Wild poliovirus type 1 and type 3 importations—15 countries, Africa, 2008–2009. MMWR Morb Mortal Wkly Rep. 2009;58:357–62.Google Scholar
  178. 178.
    World Health Organization. Poliomyelitis in Tajikistan—update. Wkly Epidemiol Rec. 2010;85:165–6.Google Scholar
  179. 179.
    Mulders MN, Lipskaya GY, van der Avoort HGAM, Koopmans MPG, Kew OM, van Loon AM. Molecular epidemiology of wild poliovirus type 1 in Europe, the Middle East, and the Indian Subcontinent. J Infect Dis. 1995;171:1399–405.PubMedGoogle Scholar
  180. 180.
    Patriarca PA, Sutter RW, Oostvogel PM. Outbreaks of paralytic poliomyelitis, 1976–1995. J Infect Dis. 1997;175 Suppl 1:S165–72.PubMedGoogle Scholar
  181. 181.
    Centers for Disease Control and Prevention. Outbreaks following wild poliovirus importations—Europe, Africa, and Asia, January 2009–September 2010. MMWR Morb Mortal Wkly Rep. 2010;59:1393–9.Google Scholar
  182. 182.
    Afif H, Sutter RW, Fontaine RE, et al. Outbreak of poliomyelitis in Gizan, Saudi Arabia: co-circulation of wild type 1 polioviruses from three separate origins. J Infect Dis. 1997;175 Suppl 1:S71–5.PubMedGoogle Scholar
  183. 183.
    Estívariz C, Watkins MA, Handoko D, et al. A large vaccine-derived poliovirus outbreak on Madura Island—Indonesia, 2005. J Infect Dis. 2008;197:347–54.PubMedGoogle Scholar
  184. 184.
    World Health Organization. Progress towards eradicating poliomyelitis: Afghanistan and Pakistan, January 2011–August 2012. Wkly Epidemiol Rec. 2012;87:381–8.Google Scholar
  185. 185.
    World Health Organization. Progress towards poliomyelitis eradication, Nigeria, January 2011–September 2012. Wkly Epidemiol Rec. 2012;87:439–46.Google Scholar
  186. 186.
    Kew OM, Sutter RW, Nottay B, et al. Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient. J Clin Microbiol. 1998;36:2893–9.PubMedPubMedCentralGoogle Scholar
  187. 187.
    Rousset D, Rakoto-Andrianarivelo M, Razafindratsimandresy R, et al. Recombinant vaccine-derived poliovirus in Madagascar. Emerg Infect Dis. 2003;9:885–7.PubMedPubMedCentralGoogle Scholar
  188. 188.
    Yang C-F, Naguib T, Yang S-J, et al. Circulation of endemic type 2 vaccine-derived poliovirus in Egypt, 1983 to 1993. J Virol. 2003;77:8366–77.PubMedPubMedCentralGoogle Scholar
  189. 189.
    Shimizu H, Thorley B, Paladin FJ, et al. Circulation of type 1 vaccine-derived poliovirus in the Philippines in 2001. J Virol. 2004;78:13512–21.PubMedPubMedCentralGoogle Scholar
  190. 190.
    Yan D, Li L, Zhu S, et al. Emergence and localized circulation of a vaccine-derived poliovirus in an isolated mountain community in Guangxi, China. J Clin Microbiol. 2010;48:3274–80.PubMedPubMedCentralGoogle Scholar
  191. 191.
    Martín J, Odoom K, Tuite G, et al. Long-term excretion of vaccine-derived poliovirus by a healthy child. J Virol. 2004;78:13839–47.PubMedPubMedCentralGoogle Scholar
  192. 192.
    Shahmahmoodi S, Parvaneh N, Burns C, et al. Isolation of a type 3 vaccine-derived poliovirus (VDPV) from an Iranian child with X-linked agammaglobulinemia. Virus Res. 2008;137:168–72.PubMedGoogle Scholar
  193. 193.
    Shulman LM, Handsher R, Yang S-J, et al. Resolution of the pathways of poliovirus type 1 transmission during an outbreak. J Clin Microbiol. 2000;38:945–52.PubMedPubMedCentralGoogle Scholar
  194. 194.
    World Health Organization. Progress towards poliomyelitis eradication in Egypt, 2001. Wkly Epidemiol Rec. 2002;77:70–4.Google Scholar
  195. 195.
    Centers for Disease Control and Prevention. Laboratory surveillance for wild and vaccine-derived polioviruses—worldwide, January 2007–June 2008. MMWR Morb Mortal Wkly Rep. 2008;57:967–70.Google Scholar
  196. 196.
    El-Sayed N, El-Gamal Y, Abbassy AA, et al. Monovalent type 1 oral poliovirus vaccine in newborns. N Engl J Med. 2008;359:1655–65.PubMedGoogle Scholar
  197. 197.
    Mohammed AJ, AlAwaidy S, Bawikar S, et al. Fractional doses of inactivated poliovirus vaccine in Oman. N Engl J Med. 2010;362:2351–9.PubMedGoogle Scholar
  198. 198.
    John TJ, Jain H, Ravishankar K, et al. Monovalent type 1 oral poliovirus vaccine among infants in India: report of two randomized double-blind controlled clinical trials. Vaccine. 2011;29:5793–801.PubMedGoogle Scholar
  199. 199.
    Estívariz CF, Jafari H, Sutter RW, et al. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6–9 months in Moradabad, India: a community-based, randomised controlled trial. Lancet Infect Dis. 2012;12:128–35.PubMedGoogle Scholar
  200. 200.
    Resik S, Tejeda A, Sutter RW, et al. Priming after a fractional dose of inactivated poliovirus vaccine. N Engl J Med. 2013;368:416–24.PubMedGoogle Scholar
  201. 201.
    Pallansch MA, Roos RP. Enteroviruses: polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses. In: Knipe DM, Howley PM, Griffin DE, et al., editors. Fields virology. 5th ed. Philadelphia: Lippincott Williams and Wilkins; 2007. p. 839–93.Google Scholar
  202. 202.
    Racaniello VR. Picornaviridae: the viruses and their replication. In: Knipe DM, Howley PM, Griffin DE, et al., editors. Fields virology. 5th ed. Philadelphia: Lippincott Williams and Wilkins; 2007. p. 795–838.Google Scholar
  203. 203.
    Hogle JM, Chow M, Filman DJ. The three-dimensional structure of poliovirus at 2.9 Å resolution. Science. 1985;229:1358–65.PubMedGoogle Scholar
  204. 204.
    Toyoda H, Kohara M, Kataoka Y, et al. Complete nucleotide sequences of all three poliovirus serotype genomes: implication for genetic relationship, gene function and antigenic determinants. J Mol Biol. 1984;174:561–85.PubMedGoogle Scholar
  205. 205.
    Guillot S, Caro V, Cuervo N, et al. Natural genetic exchanges between vaccine and wild poliovirus strains in humans. J Virol. 2000;74:8434–43.PubMedPubMedCentralGoogle Scholar
  206. 206.
    Liu H-M, Zheng D-P, Zhang L-B, Oberste MS, Kew OM, Pallansch MA. Serial recombination during circulation of type 1 wild-vaccine recombinant polioviruses in China. J Virol. 2003;77:10994–1005.PubMedPubMedCentralGoogle Scholar
  207. 207.
    Minor PD, Almond JW. Poliovirus vaccines: molecular biology and immune response. In: Semler BL, Wimmer E, editors. Molecular biology of picornaviruses. Washington, D.C.: ASM Press; 2002. p. 381–90.Google Scholar
  208. 208.
    Mendelsohn CL, Wimmer E, Racaniello VR. Cellular receptor for poliovirus: molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily. Cell. 1989;56:855–65.PubMedGoogle Scholar
  209. 209.
    Gromeier M, Nomoto A. Determinants of poliovirus pathogenesis. In: Semler BL, Wimmer E, editors. Molecular biology of picornaviruses. Washington, D.C.: ASM Press; 2002. p. 367–79.Google Scholar
  210. 210.
    Hogle JM. Poliovirus cell entry: common structural themes in viral cell entry pathways. Annu Rev Microbiol. 2002;56:677–702.PubMedPubMedCentralGoogle Scholar
  211. 211.
    Le Bouvier GL. The D to C change in poliovirus particles. Br J Exp Pathol. 1959;40:605–20.PubMedCentralGoogle Scholar
  212. 212.
    Wallis C, Menick JL. Cationic stabilization—a new property of enteroviruses. Virology. 1962;16:504–6.PubMedGoogle Scholar
  213. 213.
    Melnick JL, Ashkenazi A, Midulla VC, Wallis C, Bernstein A. Immunogenic potency of magnesium chloride-stabilized oral poliovaccine. J Am Med Assoc. 1963;185:406–8.Google Scholar
  214. 214.
    Rueckert RR. Picornaviridae: the viruses and their replication. In: Fields BN, Knipe DM, Howley PM, editors. Fields virology. 3rd ed. Philadelphia: Lippincott-Raven Publishers; 1996. p. 609–54.Google Scholar
  215. 215.
    Minor PD, Dunn G, Evans DMA, et al. The temperature sensitivity of the Sabin type 3 vaccine strain of poliovirus: molecular and structural effects of a mutation in the capsid protein VP3. J Gen Virol. 1989;70:1117–23.PubMedGoogle Scholar
  216. 216.
    Lentz KN, Smith AD, Geisler SC, et al. Structure of poliovirus type 2 Lansing complexed with antiviral agent SCH48973: comparison of the structural and biological properties of three poliovirus serotypes. Structure. 1997;5:961–78.PubMedGoogle Scholar
  217. 217.
    Rueckert RR, Pallansch MA. Preparation and characterization of encephalomyocarditis (EMC) virus. Methods Enzymol. 1981;78:315–25.PubMedGoogle Scholar
  218. 218.
    Page GS, Mosser AG, Hogle JM, Filman DJ, Rueckert RR, Chow M. Three-dimensional structure of poliovirus serotype 1 neutralizing determinants. J Virol. 1988;62:1781–94.PubMedPubMedCentralGoogle Scholar
  219. 219.
    Filman DJ, Syed R, Chow M, Macadam AJ, Minor PD, Hogle JM. Structural factors that control conformational transitions and serotype specificity in type 3 poliovirus. EMBO J. 1989;8:1567–79.PubMedPubMedCentralGoogle Scholar
  220. 220.
    Huovilainen A, Kinnunen L, Ferguson M, Hovi T. Antigenic variation among 173 strains of type 3 poliovirus isolated in Finland during the 1984 to 1985 outbreak. J Gen Virol. 1988;69:1941–8.PubMedGoogle Scholar
  221. 221.
    Shulman L, Manor J, Handsher R, et al. Molecular and antigenic characterization of a highly evolved derivative of the type 2 oral poliovaccine strain isolated from sewage in Israel. J Clin Microbiol. 2000;38:3729–34.PubMedPubMedCentralGoogle Scholar
  222. 222.
    Yakovenko ML, Cherkasova EA, Rezapkin GV, et al. Antigenic evolution of vaccine-derived polioviruses: changes in individual epitopes and relative stability of the overall immunological properties. J Virol. 2006;80:2641–53.PubMedPubMedCentralGoogle Scholar
  223. 223.
    DeVries AS, Harper J, Murray A, et al. Vaccine-derived poliomyelitis 12 years after infection in Minnesota. N Engl J Med. 2011;364:2316–23.PubMedGoogle Scholar
  224. 224.
    Harber J, Bernhardt G, Lu H-H, Sgro JY, Wimmer E. Canyon rim residues, including antigenic determinants, modulate serotype-specific binding of polioviruses to mutants of the poliovirus receptor. Virology. 1995;214:559–70.PubMedGoogle Scholar
  225. 225.
    He Y-N, Bowman VD, Mueller S, et al. Interaction of the poliovirus receptor with poliovirus. Proc Natl Acad Sci U S A. 2000;97:79–84.PubMedPubMedCentralGoogle Scholar
  226. 226.
    Melnick JL. Antigenic crossings within poliovirus types. Proc Soc Exp Biol Med. 1955;89:131–3.PubMedGoogle Scholar
  227. 227.
    Uhlig J, Wiegers K, Dernick R. A new antigenic site of poliovirus recognized by an intertypic cross-neutralizing monoclonal-antibody. Virology. 1990;178:606–10.PubMedGoogle Scholar
  228. 228.
    Chen ZC, Chumakov K, Dragunsky E, et al. Chimpanzee-human monoclonal antibodies for treatment of chronic poliovirus excretors and emergency postexposure prophylaxis. J Virol. 2011;85:4354–62.PubMedPubMedCentralGoogle Scholar
  229. 229.
    Roizman B, Mayer MM, Roane Jr PR. Immunochemical studies of poliovirus. IV. Alteration of the immunologic specificity of purified poliomyelitis virus by heat and ultraviolet light. J Immunol. 1959;82:19–25.PubMedGoogle Scholar
  230. 230.
    Dowdle WR, Birmingham ME. The biologic principles of poliovirus eradication. J Infect Dis. 1997;175 Suppl 1:S286–92.PubMedGoogle Scholar
  231. 231.
    Allmond BW, Froeschle JE, Guilloud NB. Paralytic poliomyelitis in large laboratory primates: virologic investigation and report on the use of oral poliomyelitis virus (OPV) vaccine. Am J Epidemiol. 1967;85:229–39.PubMedGoogle Scholar
  232. 232.
    Koike S, Nomoto A. Poliomyelitis. In: Ehrenfeld E, Domingo E, Roos R, editors. The picornaviruses. Washington, D.C.: ASM Press; 2010. p. 339–51.Google Scholar
  233. 233.
    Howe HA, Bodian D. Poliomyelitis in the chimpanzee: a clinical-pathologic study. Bull Johns Hopkins Hosp. 1941;69:149–69.Google Scholar
  234. 234.
    Morbeck ME, Zihlman AL, Sumner DRJ, Galloway A. Poliomyelitis and skeletal asymmetry in Gombe chimpanzees. Primates. 1991;32:77–91.Google Scholar
  235. 235.
    Howe HA, Bodian D. Poliomyelitis in the cynomolgus monkey following oral inoculation. Am J Hyg. 1948;48:99–106.PubMedGoogle Scholar
  236. 236.
    Melnick JL, Von Magnus H. Comparative susceptibility of cynomolgus and other monkey species to poliomyelitis virus by the intracerebral and oral routes. Am J Hyg. 1948;48:107–12.PubMedGoogle Scholar
  237. 237.
    Sabin AB, Hennessen WA, Winsser J. Studies of variants of poliomyelitis virus. J Exp Med. 1954;99:551–76.PubMedPubMedCentralGoogle Scholar
  238. 238.
    Crotty S, Lohman BL, Lu FX-S, Tang S, Miller CJ, Andino R. Mucosal immunization of cynomolgus macaques with two serotypes of live poliovirus vectors expressing simian immunodeficiency virus antigens: stimulation of humoral, mucosal, and cellular immunity. J Virol. 1999;73:9485–95.PubMedPubMedCentralGoogle Scholar
  239. 239.
    Ida-Hosonuma M, Sasaki Y, Toyoda H, et al. Host range of poliovirus is restricted to simians because of a rapid sequence change of the poliovirus receptor gene during evolution. Arch Virol. 2003;148:29–44.PubMedGoogle Scholar
  240. 240.
    Khan S, Peng X, Yin J, Zhang P, Wimmer E. Characterization of the New World monkey homologues of human poliovirus receptor CD155. J Virol. 2008;82:7167–79.PubMedPubMedCentralGoogle Scholar
  241. 241.
    Shelokov A, Habel K, McKinstry DW. Relation of poliomyelitis virus types to clinical disease and geographic distribution: a preliminary report. Ann N Y Acad Sci. 1955;61:998–1004.PubMedGoogle Scholar
  242. 242.
    Bodian D. Emerging concept of poliomyelitis infection. Science. 1955;122:105–8.PubMedGoogle Scholar
  243. 243.
    Sabin AB. Pathogenesis of poliomyelitis: reappraisal in light of new data. Science. 1956;123:1151–6.PubMedGoogle Scholar
  244. 244.
    Minor PD. Poliomyelitis. In: Nathanson N, editor. Viral pathogenesis. Philadelphia: Lippincott-Raven; 1997. p. 555–74.Google Scholar
  245. 245.
    Armstrong C. The experimental transmission of poliomyelitis to the Eastern cotton rat, Sigmodon hispidus hispidus. Public Health Rep. 1939;54:1719–21.Google Scholar
  246. 246.
    Li CP, Habel K. Adaptation of Leon strain of poliomyelitis to mice. Proc Soc Exp Biol Med. 1951;78:233–8.PubMedGoogle Scholar
  247. 247.
    Li CP, Schaeffer M. Adaptation of type 1 poliovirus to mice. Proc Soc Exp Biol Med. 1953;82:477–81.PubMedGoogle Scholar
  248. 248.
    Roca-Garcia M, Koprowski H, Jervis GA, Norton TW, Nelson TL, Cox HR. Immunization of humans with a chick embryo adapted strain of MEF1 poliomyelitis virus. J Immunol. 1956;77:123–31.PubMedGoogle Scholar
  249. 249.
    Holland JJ, McLaren LC, Syverton JT. The mammalian cell-virus relationship. IV. Infection of naturally insusceptible cells with enterovirus ribonucleic acid. J Exp Med. 1959;110:65–80.PubMedPubMedCentralGoogle Scholar
  250. 250.
    Miller DA, Miller OJ, Dev VG, et al. Human chromosome 19 carries a poliovirus receptor gene. Cell. 1974;1:167–73.Google Scholar
  251. 251.
    Maier MK, Seth S, Czeloth N, et al. The adhesion receptor CD155 determines the magnitude of humoral immune responses against orally ingested antigens. Eur J Immunol. 2007;37:2214–25.PubMedGoogle Scholar
  252. 252.
    De Jesus N. Epidemics to eradication: the modern history of poliomyelitis. Virol J. 2007;4:70.PubMedPubMedCentralGoogle Scholar
  253. 253.
    Arita M, Koike S, Aoki J, Horie H, Nomoto A. Interaction of poliovirus with its purified receptor and conformational alteration of the virion. J Virol. 1998;72:3578–86.PubMedPubMedCentralGoogle Scholar
  254. 254.
    Belnap DM, McDermott BM, Filman DJ, et al. Three-dimensional structure of poliovirus receptor bound to poliovirus. Proc Natl Acad Sci U S A. 2000;97:73–8.PubMedPubMedCentralGoogle Scholar
  255. 255.
    He Y, Mueller S, Chipman PR, et al. Complexes of poliovirus serotypes with their common cellular receptor, CD155. J Virol. 2003;77:4827–35.PubMedPubMedCentralGoogle Scholar
  256. 256.
    Bergelson JM. Receptors. In: Ehrenfeld E, Domingo E, Roos R, editors. The picornaviruses. Washington, D.C.: ASM Press; 2010. p. 73–86.Google Scholar
  257. 257.
    Levy H, Bostina M, Filman DJ, Hogle JM. Cell entry: a biochemical and structural perspective. In: Ehrenfeld E, Domingo E, Roos R, editors. The picornaviruses. Washington, D.C.: ASM Press; 2010. p. 87–104.Google Scholar
  258. 258.
    Palmenberg A, Neubauer D, Skern T. Genome organization and encoded proteins. In: Ehrenfeld E, Domingo E, Roos R, editors. The picornaviruses. Washington, D.C.: ASM Press; 2010. p. 3–17.Google Scholar
  259. 259.
    Wimmer E, Paul A. The making of a picornavirus genome. In: Ehrenfeld E, Domingo E, Roos R, editors. The picornaviruses. Washington, D.C.: ASM Press; 2010. p. 33–55.Google Scholar
  260. 260.
    Martínez-Salas E, Ryan MD. Translation and protein processing. In: Ehrenfeld E, Domingo E, Roos R, editors. The picornaviruses. Washington, D.C.: ASM Press; 2010. p. 141–61.Google Scholar
  261. 261.
    Dougherty JD, Park N, Gustin KE, Lloyd RE. Interference with cellular gene expression. In: Ehrenfeld E, Domingo E, Roos R, editors. The picornaviruses. Washington, D.C.: ASM Press; 2010. p. 165–80.Google Scholar
  262. 262.
    Kirkegaard K, Semler BL. Genome replication II: the process. In: Ehrenfeld E, Domingo E, Roos R, editors. The picornaviruses. Washington, D.C.: ASM Press; 2010. p. 127–40.Google Scholar
  263. 263.
    Rozovics JM, Semler BL. Genome replication I: the players. In: Ehrenfeld E, Domingo E, Roos R, editors. The picornaviruses. Washington, D.C.: ASM Press; 2010. p. 107–25.Google Scholar
  264. 264.
    Bodian D. Histopathologic basis of clinical findings in poliomyelitis. Am J Med. 1949;6:563–78.PubMedGoogle Scholar
  265. 265.
    Jenkins GM, Rambaut A, Pybus OG, Holmes EC. Rates of molecular evolution in RNA viruses: a quantitative phylogenetic analysis. J Mol Evol. 2002;54:156–65.PubMedGoogle Scholar
  266. 266.
    de la Torre JC, Giachetti C, Semler BL, Holland JJ. High frequency of single- base transitions and extreme frequency of precise multiple-base reversion mutations in poliovirus. Proc Natl Acad Sci U S A. 1992;89:2531–5.PubMedPubMedCentralGoogle Scholar
  267. 267.
    Drake JW. Rates of spontaneous mutation among RNA viruses. Proc Natl Acad Sci U S A. 1993;90:4171–5.PubMedPubMedCentralGoogle Scholar
  268. 268.
    Wimmer E, Hellen CU, Cao X. Genetics of poliovirus. Annu Rev Genet. 1993;27:353–436.PubMedGoogle Scholar
  269. 269.
    Wells VR, Plotch SJ, DeStefano JJ. Determination of the mutation rate of poliovirus RNA-dependent RNA polymerase. Virus Res. 2001;74:119–32.PubMedGoogle Scholar
  270. 270.
    Arnold JJ, Cameron CE. Poliovirus RNA-dependent RNA polymerase (3Dpol): pre-steady-state kinetic analysis of ribonucleotide incorporation in the presence of Mg2+. Biochemistry. 2004;43:5126–37.PubMedPubMedCentralGoogle Scholar
  271. 271.
    Runckel C, Westesson O, Andino R, DeRisi JL. Identification and manipulation of the molecular determinants influencing poliovirus recombination. PLoS Pathog. 2013;9:e1003164.PubMedPubMedCentralGoogle Scholar
  272. 272.
    Domingo E, Escarmís C, Sevilla N, et al. Basic concepts in RNA virus evolution. FASEB J. 1996;10:859–64.PubMedGoogle Scholar
  273. 273.
    Agol VI. Picornavirus genetics: an overview. In: Semler BL, Wimmer E, editors. Molecular biology of picornaviruses. Washington, D.C.: ASM Press; 2002. p. 269–84.Google Scholar
  274. 274.
    Domingo E. Virus evolution. In: Knipe DM, Howley PM, editors. Fields virology. 5th ed. Philadelphia: Lippincott Williams and Wilkins; 2007. p. 389–421.Google Scholar
  275. 275.
    Chumakov KM, Norwood LP, Parker ML, Dragunsky EM, Ran YX, Levenbook IS. RNA sequence variants in live poliovirus vaccine and their relation to neurovirulence. J Virol. 1992;66:966–70.PubMedPubMedCentralGoogle Scholar
  276. 276.
    Minor PD, Ferguson M, Evans DMA, Almond JW, Icenogle JP. Antigenic structure of polioviruses of serotypes 1, 2, and 3. J Gen Virol. 1986;67:1283–91.PubMedGoogle Scholar
  277. 277.
    Cooper PD. Genetics of picornaviruses. In: Fraenkel-Conrat H, Wagner R, editors. Comprehensive virology. New York: Plenum Press; 1977. p. 133–207.Google Scholar
  278. 278.
    Tolskaya EA, Romanova LI, Kolesnikova MS, Agol VI. Intertypic recombination in poliovirus: genetic and biochemical studies. Virology. 1983;124:121–32.PubMedGoogle Scholar
  279. 279.
    Cammack N, Phillips A, Dunn G, Patel V, Minor PD. Intertypic genomic rearrangements of poliovirus strains in vaccinees. Virology. 1988;167:507–14.PubMedGoogle Scholar
  280. 280.
    Arita M, Zhu SL, Yoshida H, Yoneyama T, Miyamura T, Shimizu H. A Sabin 3-derived poliovirus recombinant contained a sequence homologous with indigenous human enterovirus species C in the viral polymerase coding region. J Virol. 2005;79:12650–7.PubMedPubMedCentralGoogle Scholar
  281. 281.
    Escarmís C, Dávila M, Charpentier N, Bracho A, Moya A, Domingo E. Genetic lesions associated with Muller’s ratchet in an RNA virus. J Mol Biol. 1996;264:255–67.PubMedGoogle Scholar
  282. 282.
    Agol VI. Picornaviruses as a model for studying the nature of RNA recombination. In: Ehrenfeld E, Domingo E, Roos R, editors. The picornaviruses. Washington, D.C.: ASM Press; 2010. p. 239–52.Google Scholar
  283. 283.
    Combelas N, Holmblat B, Joffret M-L, Colbère-Garapin F, Delpeyroux F. Recombination between poliovirus and coxsackie A viruses of species C: a model of viral genetic plasticity and emergence. Viruses. 2011;3:1460–84.PubMedPubMedCentralGoogle Scholar
  284. 284.
    Fenner F, Henderson DA, Arita I, Ježek Z, Ladnyi ID. Smallpox and its eradication. Geneva: World Health Organization; 1988.Google Scholar
  285. 285.
    Kim-Farley RJ, Dave KH, Sokhey J, Mandke VB. Poliomyelitis surveillance and vaccine efficacy in Bombay, 1982–87. Bull World Health Organ. 1989;67:663–7.PubMedPubMedCentralGoogle Scholar
  286. 286.
    Mandke BV, Pawar RM, Naik DD, Torne VP, Naiksatam AM. Review of poliomyelitis in Bombay (1982–1989): observations on the improved immunisation coverage. Indian J Public Health. 1990;34:200–8.PubMedGoogle Scholar
  287. 287.
    Peart AF, Rhodes AJ. An outbreak of poliomyelitis in Canadian Eskimos in wintertime. Can J Public Health. 1949;40:405–19.PubMedGoogle Scholar
  288. 288.
    Moses SH. Report on the epidemic of anterior poliomyelitis in the Nicobar Islands. Ind Med Gaz. 1948;83:355–63.Google Scholar
  289. 289.
    World Health Organization. Progress towards poliomyelitis eradication, Indonesia, 1995. Wkly Epidemiol Rec. 1996;71:253–5.Google Scholar
  290. 290.
    World Health Organization. Final stages of polio eradication WHO Western Pacific Region, 1997–1998. Wkly Epidemiol Rec. 1999;74:20–4.Google Scholar
  291. 291.
    Más Lago P, Cáceres VM, Galindo MA, et al. Persistence of vaccine-derived poliovirus following a mass vaccination campaign in Cuba: implications for stopping polio vaccination after global eradication. Int J Epidemiol. 2001;30:1029–34.PubMedGoogle Scholar
  292. 292.
    Gear JHS. Poliomyelitis in under-developed areas of the world. In: Poliomyelitis, vol. World Health Organization monograph series no. 26. Geneva: World Health Organization; 1955. p. 31–58.Google Scholar
  293. 293.
    Hemmes J, Winkler K, Kool S. Virus survival as a seasonal factor in influenza and poliomyelitis. Antonie Van Leeuwenhoek. 1962;28:221–33.PubMedGoogle Scholar
  294. 294.
    Sabin AB, Ramos-Alvarez M, Alvarez-Amezquita J, et al. Live, orally given poliovirus vaccine. Effects of rapid mass immunization on population under conditions of massive enteric infection with other viruses. J Am Med Assoc. 1960;173:1521–6.Google Scholar
  295. 295.
    Cruz RR. Cuba: mass polio vaccination program, 1962–1982. Rev Infect Dis. 1984;6 Suppl 2:S408–12.Google Scholar
  296. 296.
    Risi JB. The control of poliomyelitis in Brazil. Rev Infect Dis. 1984;6 Suppl 2:S400–3.Google Scholar
  297. 297.
    Wang K-A, Zhang L-B, Otten Jr MW, et al. Status of the eradication of indigenous wild poliomyelitis in the People’s Republic of China. J Infect Dis. 1997;175 Suppl 1:S105–12.PubMedGoogle Scholar
  298. 298.
    Zhang J, Zhang LB, Otten Jr MW, et al. Surveillance for polio eradication in the People’s Republic of China. J Infect Dis. 1997;175 Suppl 1:S122–34.PubMedGoogle Scholar
  299. 299.
    Onadeko MO, Familusi JB. Observations on the age and spatial distribution of paralytic poliomyelitis in Ibadan, Nigeria. Ann Trop Paediatr. 1990;10:133–8.PubMedGoogle Scholar
  300. 300.
    Singh J, Khare S, Bhatia R, Jain DC, Sokhey J. Epidemiological characteristics of poliomyelitis in Delhi, 1997. Indian Pediatr. 1999;36:1211–9.PubMedGoogle Scholar
  301. 301.
    Schonberger LB, McGowan Jr JE, Gregg MB. Vaccine-associated poliomyelitis in the United States, 1961-1972. Am J Epidemiol. 1976;104:202–11.PubMedGoogle Scholar
  302. 302.
    Centers for Disease Control and Prevention. Notes from the field: poliomyelitis outbreak—Republic of the Congo, September 2010–February 2011. MMWR Morb Mortal Wkly Rep. 2011;60:312–3.Google Scholar
  303. 303.
    Nkowane BM, Wassilak SGF, Orenstein WA, et al. Vaccine-associated paralytic poliomyelitis, U.S.A. 1973–1984. J Am Med Assoc. 1987;257:1335–40.Google Scholar
  304. 304.
    Strebel PM, Sutter RW, Cochi SL, et al. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis. 1992;14:568–79.PubMedGoogle Scholar
  305. 305.
    Melnick JL, Ledinko N. Social serology: antibody levels in a normal young population during an epidemic of poliomyelitis. Am J Hyg. 1951;54:354–82.PubMedGoogle Scholar
  306. 306.
    Kew OM, Nottay BK. Molecular epidemiology of polioviruses. Rev Infect Dis. 1984;6 Suppl 2:S499–504.PubMedGoogle Scholar
  307. 307.
    Alexander LN, Seward JF, Santibanez TA, et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. J Am Med Assoc. 2004;292:1696–701.Google Scholar
  308. 308.
    Schonberger LB, Sullivan-Bolyai JZ, Bryan JA. Poliomyelitis in the United States. Adv Neurol. 1978;19:217–27.PubMedGoogle Scholar
  309. 309.
    Shimojo H. Poliomyelitis control in Japan. Rev Infect Dis. 1984;6 Suppl 2:S427–30.PubMedGoogle Scholar
  310. 310.
    Más Lago P. Eradication of poliomyelitis in Cuba: a historical perspective. Bull World Health Organ. 1999;77:681–7.PubMedPubMedCentralGoogle Scholar
  311. 311.
    Schonberger LB, Kaplan J, Kim-Farley R, Moore M, Eddins DL, Hatch M. Control of paralytic poliomyelitis in the United States. Rev Infect Dis. 1984;6 Suppl 2:S424–6.PubMedGoogle Scholar
  312. 312.
    Bijkerk H. Surveillance and control of poliomyelitis in the Netherlands. Rev Infect Dis. 1984;6 Suppl 2:S451–6.PubMedGoogle Scholar
  313. 313.
    Mulders MN, Reimerink JHJ, Koopmans MPG, van Loon AM, van der Avoort HGAM. Genetic analysis of wild-type poliovirus importation into the Netherlands (1979-1995). J Infect Dis. 1997;176:617–24.PubMedGoogle Scholar
  314. 314.
    Oostvogel PM, van Wijngaarden JK, van der Avoort HGAM, et al. Poliomyelitis outbreak in an unvaccinated community in the Netherlands. Lancet. 1994;344:665–70.PubMedGoogle Scholar
  315. 315.
    Mulders MN, van Loon AM, van der Avoort HGAM, et al. Molecular characterization of the wild poliovirus type 3 epidemic in the Netherlands (1992-93). J Clin Microbiol. 1995;33:3252–6.PubMedPubMedCentralGoogle Scholar
  316. 316.
    Pöyry T, Kinnunen L, Kapsenberg J, Kew O, Hovi T. Type 3 poliovirus/Finland/1984 is genetically related to common Mediterranean strains. J Gen Virol. 1990;71:2535–41.PubMedGoogle Scholar
  317. 317.
    Lipskaya GY, Chervonskaya EA, Belova GI, et al. Geographic genotypes (geotypes) of poliovirus case isolates from the Former Soviet Union: relatedness to other known poliovirus genotypes. J Gen Virol. 1995;76:1687–99.PubMedGoogle Scholar
  318. 318.
    Kim-Farley RJ, Rutherford G, Lichfield P, et al. Outbreak of paralytic poliomyelitis, Taiwan. Lancet. 1984;2:1322–4.PubMedGoogle Scholar
  319. 319.
    Heymann DL. House-to-house and school lameness surveys in Cameroon: a comparison of two methods for estimating the prevalence and annual incidence of paralytic poliomyelitis. Rev Infect Dis. 1984;6 Suppl 2:S376–8.PubMedGoogle Scholar
  320. 320.
    Melnick JL, Proctor RO, Ocampo AR, Diwan AR, Ben-Porath E. Free and bound virus in serum after administration of oral poliovirus vaccine. Am J Epidemiol. 1966;84:329–42.PubMedGoogle Scholar
  321. 321.
    Alexander Jr JP, Gary Jr HE, Pallansch MA. Duration of poliovirus excretion and its implications for acute flaccid paralysis surveillance: a review of the literature. J Infect Dis. 1997;175:S176–82.PubMedGoogle Scholar
  322. 322.
    Draper G. Acute poliomyelitis. Philadelphia: Blackiston’s; 1917.Google Scholar
  323. 323.
    Racaniello VR. One hundred years of poliovirus pathogenesis. Virology. 2006;344:9–16.PubMedGoogle Scholar
  324. 324.
    World Health Organization. Poliomyelitis 1980, Parts 1 and 2. Wkly Epidemiol Rec. 1981;56:329–32, 37-41.Google Scholar
  325. 325.
    LaForce FM, Lichnevski MS, Keja J, Henderson RH. Clinical survey techniques to estimate prevalence and annual incidence of poliomyelitis in developing countries. Bull World Health Organ. 1980;58:609–20.PubMedPubMedCentralGoogle Scholar
  326. 326.
    Basu RN. Magnitude of problem of poliomyelitis in India. Indian Pediatr. 1981;18:507–11.PubMedGoogle Scholar
  327. 327.
    John TJ. Poliomyelitis in India: prospects and problems of control. Rev Infect Dis. 1984;6:S438–41.PubMedGoogle Scholar
  328. 328.
    Melnick JL, Rennick V. Infectivity titers of enterovirus as found in human stools. J Med Virol. 1980;5:205–20.PubMedGoogle Scholar
  329. 329.
    Koprowski H, Norton TW, Jervis GA, et al. Clinical investigations on attenuated strains of poliomyelitis virus; use as a method of immunization of children with living virus. J Am Med Assoc. 1956;160:954–66.PubMedGoogle Scholar
  330. 330.
    Ogra PL, Karzon DT. Formation and function of poliovirus antibody in different tissues. Prog Med Virol. 1971;13:156–93.Google Scholar
  331. 331.
    Dowdle WR, Wolff C. Post-eradication poliovirus facility-associated community risks. Biologicals. 2006;34:127–32.PubMedGoogle Scholar
  332. 332.
    Angez M, Shaukat S, Alam MM, Sharif S, Khurshid A, Zaidi SSZ. Genetic relationships and epidemiological links between wild type 1 poliovirus isolates in Pakistan and Afghanistan. Virol J. 2012;9:51.PubMedPubMedCentralGoogle Scholar
  333. 333.
    Nathanson N, Langmuir AD. The Cutter incident. Poliomyelitis following formaldehyde-inactivated poliovirus vaccination in the United States in the spring of 1955. II. Relationship of poliomyelitis to Cutter vaccine. Am J Hyg. 1963;78:29–60.PubMedGoogle Scholar
  334. 334.
    Offit PA. The Cutter incident: how America’s first polio vaccine led to the growing vaccine crisis. New Haven: Yale University Press; 2005.Google Scholar
  335. 335.
    Deshpande JM, Nadkarni SS, Siddiqui ZA. Detection of MEF-1 laboratory reference strain of poliovirus type 2 in children with poliomyelitis in India in 2002 & 2003. Indian J Med Res. 2003;118:217–23.PubMedGoogle Scholar
  336. 336.
    World Health Organization. Update on actions taken following the isolation of MEF-1 reference poliovirus associated with acute flaccid paralysis cases in India in late 2002 and early 2003. Wkly Epidemiol Rec. 2003;78:284.Google Scholar
  337. 337.
    Nathanson N, Bodian D. Experimental poliomyelitis following intramuscular virus injection. III. The effect of passive antibody on paralysis and viremia. Bull Johns Hopkins Hosp. 1962;111:198–220.PubMedGoogle Scholar
  338. 338.
    Nathanson N. The pathogenesis of poliomyelitis: what we don’t know. Adv Virus Res. 2008;71:1–50.PubMedGoogle Scholar
  339. 339.
    Nathanson N. David Bodian’s contribution to the development of poliovirus vaccine. Am J Epidemiol. 2005;161:207–12.PubMedGoogle Scholar
  340. 340.
    Ren R, Constantini F, Gorgacz EJ, Lee JJ, Racaniello VR. Transgenic mice expressing a human poliovirus receptor: a new model for poliomyelitis. Cell. 1990;63:353–62.PubMedGoogle Scholar
  341. 341.
    Koike S, Taya C, Kurata T, et al. Transgenic mice susceptible to poliovirus. Proc Natl Acad Sci U S A. 1991;88:951–5.PubMedPubMedCentralGoogle Scholar
  342. 342.
    Crotty S, Hix L, Sigal LJ, Andino R. Poliovirus pathogenesis in a new poliovirus receptor transgenic mouse model: age-dependent paralysis and a mucosal route of infection. J Gen Virol. 2002;83:1707–20.PubMedGoogle Scholar
  343. 343.
    Ohka S, Igarashi H, Nagata N, et al. Establishment of a poliovirus oral infection system in human poliovirus receptor-expressing transgenic mice that are deficient in alpha/beta interferon receptor. J Virol. 2007;81:7902–12.PubMedPubMedCentralGoogle Scholar
  344. 344.
    Ida-Hosonuma M, Iwasaki T, Yoshikawa T, et al. The alpha/beta interferon response controls tissue tropism and pathogenicity of poliovirus. J Virol. 2005;79:4460–9.PubMedPubMedCentralGoogle Scholar
  345. 345.
    Gromeier M, Wimmer E. Mechanism of injury-provoked poliomyelitis. J Virol. 1998;72:5056–60.PubMedPubMedCentralGoogle Scholar
  346. 346.
    Mueller S, Cao X, Welker R, Wimmer E. Interaction of the poliovirus receptor CD155 with the dynein light chain Tctex-1 and its implication for poliovirus pathogenesis. J Biol Chem. 2002;277:7897–904.PubMedGoogle Scholar
  347. 347.
    Gelfand HM, Fox JP, Leblanc DR, Elveback L. Studies on the development of natural immunity to poliomyelitis in Louisiana. V. Passive transfer of polioantibody from mother to fetus, and natural decline and disappearance of antibody in the infant. J Immunol. 1960;85:46–55.PubMedGoogle Scholar
  348. 348.
    Ogra PL, Fishaut M, Gallagher MR. Viral vaccination via the mucosal routes. Rev Infect Dis. 1980;2:352–69.PubMedGoogle Scholar
  349. 349.
    Ogra PL, Okayasu H, Czerkinsky C, Sutter RW. Mucosal immunity to poliovirus. Expert Rev Vaccines. 2011;10:1389–92.PubMedGoogle Scholar
  350. 350.
    Sabin AB. Experimental poliomyelitis by the tonsillopharyngeal route: with special reference to the influence of tonsillectomy on the development of bulbar poliomyelitis. J Am Med Assoc. 1938;111:605–10.Google Scholar
  351. 351.
    Paffenbarger Jr RS, Wilson VO. Previous tonsillectomy and current pregnancy as they affect risk of poliomyelitis attack. Ann NY Acad Sci. 1955;61:856–68.PubMedGoogle Scholar
  352. 352.
    Ogra PL. Effect of tonsillectomy and adenoidectomy on nasopharyngeal antibody response to poliovirus. N Engl J Med. 1971;284:59–64.PubMedGoogle Scholar
  353. 353.
    Sutter RW, Prevots R. Vaccine-associated paralytic poliomyelitis among immunodeficient persons. Infect Med. 1994;11:426–38.Google Scholar
  354. 354.
    Khetsuriani N, Prevots DR, Quick L, et al. Persistence of vaccine-derived polioviruses among immunodeficient persons with vaccine-associated paralytic poliomyelitis. J Infect Dis. 2003;188:1845–52.PubMedGoogle Scholar
  355. 355.
    Dalakas MC. The post-polio syndrome as an evolved clinical entity. Definition and clinical description. Ann N Y Acad Sci. 1995;753:68–80.PubMedGoogle Scholar
  356. 356.
    Ramlow J, Alexander M, LaPorte R, Kaufmann C, Kuller L. Epidemiology of the post-polio syndrome. Am J Epidemiol. 1992;136:769–86.PubMedGoogle Scholar
  357. 357.
    Melchers W, de Visser M, Jongen P, et al. The postpolio syndrome: no evidence for poliovirus persistence. Ann Neurol. 1992;32:728–32.PubMedGoogle Scholar
  358. 358.
    Banerjee K, Hlady WG, Andrus JK, Sarkar S, Fitzsimmons J, Abeykoon P. Poliomyelitis surveillance: the model used in India for polio eradication. Bull World Health Organ. 2000;78:321–9.PubMedPubMedCentralGoogle Scholar
  359. 359.
    Andrus JK, Strebel PM, de Quadros CA, Olive JM. Risk of vaccine-associated paralytic poliomyelitis in Latin America, 1989–91. Bull World Health Organ. 1995;73:33–40.PubMedPubMedCentralGoogle Scholar
  360. 360.
    Brodie M, Park WH. Active immunization against poliomyelitis. Am J Public Health. 1936;26:119–25.Google Scholar
  361. 361.
    Kolmer JA. Vaccination against acute anterior poliomyelitis. Am J Public Health. 1936;26:126–35.Google Scholar
  362. 362.
    Leake JP. Poliomyelitis following vaccination against this disease. J Am Med Assoc. 1935;105:2152.Google Scholar
  363. 363.
    Morgan IM. Immunization of monkeys with formalin-inactivated poliomyelitis viruses. Am J Epidemiol. 1948;48:394–406.Google Scholar
  364. 364.
    Enders JF, Weller TH, Robbins FC. Alterations in pathogenicity for monkeys of Brunhilde strain of poliomyelitis virus following cultivation in human tissues. Fed Proc. 1952;11:467.Google Scholar
  365. 365.
    Ferguson M, Wood DJ, Minor PD. Antigenic structure of poliovirus in inactivated vaccines. J Gen Virol. 1993;74:685–90.PubMedGoogle Scholar
  366. 366.
    van Wezel AL, van Steenis G, van der Marel P, Osterhaus AD. Inactivated poliovirus vaccine: current production methods and new developments. Rev Infect Dis. 1984;6 Suppl 2:S335–40.PubMedGoogle Scholar
  367. 367.
    Theiler M, Smith HH. The effect of prolonged cultivation in vitro upon the pathogenicity of yellow fever virus. J Exp Med. 1937;65:767–86.PubMedPubMedCentralGoogle Scholar
  368. 368.
    Theiler M. A mutant strain of the Lansing virus. In: Mechanisms of immunity in poliomyelitis. Baltimore: Department of Epidemiology, School of Public Health and Hygiene, the Johns Hopkins University; 1946. p. 29–36.Google Scholar
  369. 369.
    Li CP, Schaeffer M. Isolation of a non-neurotropic variant of type 1 poliomyelitis virus. Proc Soc Exp Biol Med. 1954;87:148–53.PubMedGoogle Scholar
  370. 370.
    Sabin AB, Boulger LR. History of Sabin attenuated poliovirus oral live vaccine strains. J Biol Stand. 1973;1:115–8.Google Scholar
  371. 371.
    Cabasso VJ, Jervis GA, Moyer AW, Roca-Garcia M, Orsi EV, Cox HR. Cumulative testing experience with consecutive lots of oral poliomyelitis vaccine. Live poliovirus vaccines First International Conference on Live Poliovirus Vaccines. Washington, D.C: Pan American Sanitary Bureau; 1959. p. 102–34.Google Scholar
  372. 372.
    Pan American Health Organization. Live Poliovirus Vaccines. Washington, D.C.: Special Publications of the Pan American Health Organization, Nos. 44 and 50; 1959, 1960.Google Scholar
  373. 373.
    Payne AMM. Field safety and efficacy of live attenuated poliovirus vaccines. Poliomyelitis papers and discussion presented at the fifth international poliomyelitis conference. Philadelphia: J.B. Lippincott; 1961. p. 257–61.Google Scholar
  374. 374.
    Racaniello VR, Ren R. Poliovirus biology and pathogenesis. Curr Top Microbiol Immunol. 1996;206:305–25.PubMedGoogle Scholar
  375. 375.
    Kitamura N, Semler BL, Rothberg PG, et al. Primary structure, gene organization and polypeptide expression of poliovirus RNA. Nature. 1981;291:547–53.PubMedGoogle Scholar
  376. 376.
    Racaniello VR, Baltimore D. Molecular cloning of poliovirus cDNA and determination of the complete nucleotide sequence of the viral genome. Proc Natl Acad Sci U S A. 1981;78:4887–91.PubMedPubMedCentralGoogle Scholar
  377. 377.
    Racaniello VR, Baltimore D. Cloned poliovirus complementary DNA is infectious in mammalian cells. Science. 1981;214:916–9.PubMedGoogle Scholar
  378. 378.
    Omata T, Kohara M, Kuge S, et al. Genetic analysis of the attenuation phenotype of poliovirus type 1. J Virol. 1986;58:348–58.PubMedPubMedCentralGoogle Scholar
  379. 379.
    Bouchard MJ, Lam DH, Racaniello VR. Determinants of attenuation and temperature sensitivity in the type 1 poliovirus Sabin strain. J Virol. 1995;69:4972–8.PubMedPubMedCentralGoogle Scholar
  380. 380.
    Kawamura N, Kohara M, Abe S, et al. Determinants in the 5′ noncoding region of poliovirus Sabin 1 RNA that influence the attenuation phenotype. J Virol. 1989;63:1302–9.PubMedPubMedCentralGoogle Scholar
  381. 381.
    Ren R, Moss EG, Racaniello VR. Identification of two determinants that attenuate vaccine-related type 2 poliovirus. J Virol. 1991;65:1377–82.PubMedPubMedCentralGoogle Scholar
  382. 382.
    Macadam AJ, Pollard SR, Ferguson G, et al. Genetic basis of attenuation of the Sabin type 2 vaccine strain of poliovirus in primates. Virology. 1993;192:18–26.PubMedGoogle Scholar
  383. 383.
    Westrop GD, Wareham KA, Evans DM, et al. Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine. J Virol. 1989;63:1338–44.PubMedPubMedCentralGoogle Scholar
  384. 384.
    Tardy-Panit M, Blondel B, Martin A, Tekaia F, Horaud F, Delpeyroux F. A mutation in the RNA polymerase of poliovirus type 1 contributes to attenuation in mice. J Virol. 1993;67:4630–8.PubMedPubMedCentralGoogle Scholar
  385. 385.
    Paul AV, Mugavero J, Yin J, et al. Studies on the attenuation phenotype of polio vaccines: poliovirus RNA polymerase derived from Sabin type 1 sequence is temperature sensitive in the uridylylation of VPg. Virology. 2000;272:72–84.PubMedGoogle Scholar
  386. 386.
    Rezapkin GV, Fan L, Asher DM, Fibi MR, Dragunsky EM, Chumakov KM. Mutations in Sabin 2 strain of poliovirus and stability of attenuated phenotype. Virology. 1999;258:152–60.PubMedGoogle Scholar
  387. 387.
    Stanway G, Hughes PJ, Mountford RC, et al. Comparison of the complete nucleotide sequences of the genomes of the neurovirulent poliovirus P3/Leon/37 and its attenuated Sabin vaccine derivative P3/Leon 12a1b. Proc Natl Acad Sci U S A. 1984;81:1539–43.PubMedPubMedCentralGoogle Scholar
  388. 388.
    Macadam AJ, Arnold C, Howlett J, et al. Reversion of the attenuated and temperature-sensitive phenotypes of the Sabin type 3 strain of poliovirus in vaccinees. Virology. 1989;172:408–14.PubMedGoogle Scholar
  389. 389.
    Muzychenko AR, Lipskaya GY, Maslova SV, et al. Coupled mutations in the 5′-untranslated region of the Sabin poliovirus strains during in vivo passage: structural and functional implications. Virus Res. 1991;21:111–22.PubMedGoogle Scholar
  390. 390.
    Haller AA, Stewart SR, Semler BL. Attenuation stem-loop lesions in the 5′ noncoding region of poliovirus RNA: neuronal cell-specific translation defects. J Virol. 1996;70:1467–74.PubMedPubMedCentralGoogle Scholar
  391. 391.
    Gromeier M, Bossert B, Arita M, Nomoto A, Wimmer E. Dual stem loops within the poliovirus internal ribosome entry site controls neurovirulence. J Virol. 1999;73:958–64.PubMedPubMedCentralGoogle Scholar
  392. 392.
    Svitkin Y, Cammack N, Minor PD, Almond JW. Translation deficiency of the Sabin type 3 poliovirus genome: association with an attenuating mutation C472-U. Virology. 1990;175:103–9.PubMedGoogle Scholar
  393. 393.
    Minor PD, Dunn G. The effect of sequences in the 5′ non-coding region on the replication of polioviruses in the human gut. J Gen Virol. 1988;69:1091–6.PubMedGoogle Scholar
  394. 394.
    Guest S, Pilipenko E, Sharma K, Chumakov K, Roos RP. Molecular mechanisms of attenuation of the Sabin strain of poliovirus type 3. J Virol. 2004;78:11097–107.PubMedPubMedCentralGoogle Scholar
  395. 395.
    Sutter RW, Cáceres VM, Más Lago P. The role of routine polio immunization in the post-certification era. Bull World Health Organ. 2004;82:31–9.PubMedPubMedCentralGoogle Scholar
  396. 396.
    Terry L. The association of cases of poliomyelitis with the use of type 3 oral poliomyelitis vaccines. Washington, D.C: U.S. Department of Health, Education and Welfare; 1962.Google Scholar
  397. 397.
    WHO Consultative Group. The relation between acute persisting spinal paralysis and poliomyelitis vaccine –- results of a ten-year enquiry. Bull World Health Organ. 1982;60:231–42.PubMedCentralGoogle Scholar
  398. 398.
    Esteves K. Safety of oral poliomyelitis vaccine: results of a WHO enquiry. Bull World Health Organ. 1988;66:739–46.PubMedPubMedCentralGoogle Scholar
  399. 399.
    Joce R, Wood D, Brown D, Begg N. Paralytic poliomyelitis in England and Wales, 1985–91. Br Med J. 1992;305:79–82.Google Scholar
  400. 400.
    Kohler KA, Banerjee K, Hlady GW, Andrus JK, Sutter RW. Vaccine-associated paralytic poliomyelitis in India during 1999: decreased risk despite massive use of oral polio vaccine. Bull World Health Organ. 2002;80:210–6.PubMedPubMedCentralGoogle Scholar
  401. 401.
    Centers for Disease Control and Prevention. Poliomyelitis prevention in the United States: Introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 1997;46(No. RR-3):1–25.Google Scholar
  402. 402.
    Georgescu MM, Balanant J, Macadam A, et al. Evolution of the Sabin type 1 poliovirus in humans: characterization of strains isolated from patients with vaccine-associated paralytic poliomyelitis. J Virol. 1997;71:7758–68.PubMedPubMedCentralGoogle Scholar
  403. 403.
    Lipskaya GY, Muzychenko AR, Kutitova OK, et al. Frequent isolation of intertypic poliovirus recombinants with serotype 2 specificity from vaccine-associated polio cases. J Med Virol. 1991;35:290–6.PubMedGoogle Scholar
  404. 404.
    Cuervo NS, Guillot S, Romanenkova N, et al. Genomic features of intertypic recombinant Sabin poliovirus strains excreted by primary vaccinees. J Virol. 2001;75:5740–51.PubMedPubMedCentralGoogle Scholar
  405. 405.
    Minor PD. Polio eradication, cessation of vaccination and re-emergence of disease. Nat Rev Microbiol. 2004;2:473–82.PubMedGoogle Scholar
  406. 406.
    Rosen FS, Cooper MD, Wedgwood RJP. The primary immunodeficiencies. N Engl J Med. 1995;333:431–40.PubMedGoogle Scholar
  407. 407.
    Hennessey KA, Lago H, Diomande F, et al. Poliovirus vaccine shedding among persons with HIV in Abidjan, Cote d’Ivoire. J Infect Dis. 2005;192:2124–8.PubMedGoogle Scholar
  408. 408.
    Melnick JL. Advantages and disadvantages of the killed and live poliomyelitis vaccines. Bull World Health Organ. 1978;56:21–38.PubMedPubMedCentralGoogle Scholar
  409. 409.
    World Health Organization. Progress towards poliomyelitis eradication in India, 2002. Wkly Epidemiol Rec. 2003;78:66–71.Google Scholar
  410. 410.
    Grassly NC, Wenger J, Durrani S, et al. Protective efficacy of a monovalent oral type 1 poliovirus vaccine: a case-control study. Lancet. 2007;369:1356–62.PubMedGoogle Scholar
  411. 411.
    WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines. Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in The Gambia, Oman, and Thailand. J Infect Dis. 1997;175 Suppl 1:S215–27.Google Scholar
  412. 412.
    World Health Organization. Global routine vaccination coverage, 2011. Wkly Epidemiol Rec. 2012;87:432–5.Google Scholar
  413. 413.
    Kim-Farley R, Bart K, Schonberger L, et al. The epidemiology of poliomyelitis in the United States: virtual elimination of disease caused by wild virus. Lancet. 1984;2:315–7.Google Scholar
  414. 414.
    Oker-Blom N, Penttinen K, Weckström P. Inactivated poliovirus vaccine in Finland. Rev Infect Dis. 1984;6 Suppl 2:S461–2.PubMedGoogle Scholar
  415. 415.
    Varughese PV, Carter AO, Acres SE, Furesz J. Eradication of indigenous poliomyelitis in Canada: impact of immunization strategies. Can J Public Health. 1989;80:363–8.PubMedGoogle Scholar
  416. 416.
    Emerson CI, Singer PA. Is there an ethical obligation to complete polio eradication? Lancet. 2010;375:1340–1.PubMedGoogle Scholar
  417. 417.
    Duintjer Tebbens RJ, Pallansch MA, Cochi SL, et al. Economic analysis of the global polio eradication initiative. Vaccine. 2011;29:334–43.Google Scholar
  418. 418.
    Gregg MB. Paralytic poliomyelitis can be eliminated. Rev Infect Dis. 1984;6 Suppl 2:S577–80.PubMedGoogle Scholar
  419. 419.
    Nomoto A, Arita I. Eradication of poliomyelitis. Nat Immunol. 2002;3:205–8.PubMedGoogle Scholar
  420. 420.
    Henderson RH. The expanded programme on immunization of the World Health Organization. Rev Infect Dis. 1984;6 Suppl 2:S475–9.PubMedGoogle Scholar
  421. 421.
    Castillo-Solórzano C, Marsigli C, Bravo-Alcántara P, et al. Elimination of rubella and congenital rubella syndrome in the Americas. J Infect Dis. 2011;204 Suppl 2:S571–8.PubMedGoogle Scholar
  422. 422.
    Reef SE, Strebel P, Dabbagh A, Gacic-Dobo M, Cochi S. Progress toward control of rubella and prevention of congenital rubella syndrome–worldwide, 2009. J Infect Dis. 2011;204 Suppl 1:S24–7.PubMedGoogle Scholar
  423. 423.
    World Health Organization. Progress in global control and regional elimination of measles, 2000–2011. Wkly Epidemiol Rec. 2013;88:29–36.Google Scholar
  424. 424.
    Sever J. Rotary International: a partner in polio eradication. Dev Biol (Basel). 2001;105:105–8.Google Scholar
  425. 425.
    World Health Organization. Progress towards poliomyelitis eradication, South-East Asia, 1998–1999. Wkly Epidemiol Rec. 2000;75:213–6.Google Scholar
  426. 426.
    Ku F-C, Dong D-X, Shi O-S, Niu J-T, Yang H-H. Poliomyelitis in China. J Infect Dis. 1982;146:552–7.Google Scholar
  427. 427.
    Yang B, Zhang J, Otten Jr MW, et al. Eradication of poliomyelitis: progress in the People’s Republic of China. Pediatr Infect Dis J. 1995;14:308–14.PubMedGoogle Scholar
  428. 428.
    Fine PEM, Carneiro IAM. Transmissibility and persistence of oral polio vaccine viruses: implications for the global poliomyelitis eradication initiative. Am J Epidemiol. 1999;150:1001–21.PubMedGoogle Scholar
  429. 429.
    World Health Organization. Progress towards the global eradication of poliomyelitis, 2001. Wkly Epidemiol Rec. 2002;77:98–107.Google Scholar
  430. 430.
    World Health Organization. Expanded programme on immunization–certification of poliomyelitis eradication–the Americas, 1994. Wkly Epidemiol Rec. 1994;69:293–5.Google Scholar
  431. 431.
    World Health Organization. Certification of poliomyelitis eradication, European region, June 2002. Wkly Epidemiol Rec. 2002;77:221–3.Google Scholar
  432. 432.
    World Health Organization. Progress toward global poliomyelitis eradication, 2000. Wkly Epidemiol Rec. 2001;76:126–31.Google Scholar
  433. 433.
    World Health Organization. Progress towards polio eradication, Somalia and southern Sudan. Wkly Epidemiol Rec. 1999;74:246–52.Google Scholar
  434. 434.
    Tangermann RH, Hull HF, Jafari H, Nkowane B, Everts H, Aylward RB. Eradication of poliomyelitis in countries affected by conflict. Bull World Health Organ. 2000;78:330–8.PubMedPubMedCentralGoogle Scholar
  435. 435.
    Hagiwara A, Yoneyama T, Yoshii K, et al. Genetic analysis of wild polioviruses towards the eradication of poliomyelitis from the Western Pacific Region. Jpn J Infect Dis. 1999;52:146–9.PubMedGoogle Scholar
  436. 436.
    World Health Organization. Progress towards the global eradication of poliomyelitis, 2002. Wkly Epidemiol Rec. 2003;78:138–44.Google Scholar
  437. 437.
    World Health Organization. Somalia is again polio-free. Wkly Epidemiol Rec. 2008;83:117–8.Google Scholar
  438. 438.
    World Health Organization. Progress towards eradicating poliomyelitis in India, January 2009–October 2010. Wkly Epidemiol Rec. 2010;85:497–503.Google Scholar
  439. 439.
    Chumakov K, Kew O. The poliovirus eradication initiative. In: Ehrenfeld E, Domingo E, Roos R, editors. The picornaviruses. Washington, D.C.: ASM Press; 2010. p. 449–59.Google Scholar
  440. 440.
    World Health Organization. Progress towards poliomyelitis eradication in Nigeria, January 2002 to March 2003. Wkly Epidemiol Rec. 2003;78:210–5.Google Scholar
  441. 441.
    World Health Organization. Progress towards poliomyelitis eradication in India, 2003. Wkly Epidemiol Rec. 2004;79:121–5.Google Scholar
  442. 442.
    World Health Organization. Progress towards global eradication of poliomyelitis, 2003 and January–April 2004. Wkly Epidemiol Rec. 2004;79:229–34.Google Scholar
  443. 443.
    World Health Organization. Progress towards poliomyelitis eradication in Nigeria, January 2003–March 2004. Wkly Epidemiol Rec. 2004;79:162–7.Google Scholar
  444. 444.
    World Health Organization. Progress towards interrupting wild poliovirus transmission, January 2006–May 2007. Wkly Epidemiol Rec. 2007;82:245–51.Google Scholar
  445. 445.
    World Health Organization. Progress towards interrupting of wild poliovirus transmission worldwide, January 2007–April 2008. Wkly Epidemiol Rec. 2008;83:170–6.Google Scholar
  446. 446.
    Morvan JM, Chezzi C, Gouandjika I, Reimerink JH, van der Avoort HG. The molecular epidemiology of type 1 poliovirus in Central African Republic. J Gen Virol. 1997;78:591–9.PubMedGoogle Scholar
  447. 447.
    Jenkins HE, Aylward RB, Gasasira A, et al. Implications of a circulating vaccine-derived poliovirus in Nigeria. N Engl J Med. 2010;362:2360–9.PubMedGoogle Scholar
  448. 448.
    Wassilak S, Pate MA, Wannemuehler K, et al. Outbreak of type 2 vaccine-derived poliovirus in Nigeria, 2005–2009: emergence and widespread circulation in an underimmunized population. J Infect Dis. 2011;203:898–909.PubMedPubMedCentralGoogle Scholar
  449. 449.
    World Health Organization. Advisory Committee on Poliomyelitis Eradication: recommendations on the use of bivalent oral poliovirus vaccine types 1 and 3. Wkly Epidemiol Rec. 2009;84:289–90.Google Scholar
  450. 450.
    Cochi SL, Linkins RW. The final phase of polio eradication: new vaccines and complex choices. J Infect Dis. 2012;205:169–71.PubMedGoogle Scholar
  451. 451.
    O’Reilly KM, Durry E, ul Islam O, et al. The effect of mass immunisation campaigns and new oral poliovirus vaccines on the incidence of poliomyelitis in Pakistan and Afghanistan, 2001–11: a retrospective analysis. Lancet. 2012;380:491–8.PubMedPubMedCentralGoogle Scholar
  452. 452.
    World Health Organization. 16th Informal Consultation of the Global Polio Laboratory Network, 22–23 September 2010 (http://www.polioeradication.org/Portals/0/Document/Resources/GPLN_publications/GPLN_Meeting_recommendations_2010.pdf). Geneva. 2010.
  453. 453.
    MacLennan C, Dunn G, Huissoon AP, et al. Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man. Lancet. 2004;363:1509–13.PubMedGoogle Scholar
  454. 454.
    Bellmunt A, May G, Zell R, Pring-Akerblom P, Verhagen W, Heim A. Evolution of poliovirus type I during 5.5 years of prolonged enteral replication in an immunodeficient patient. Virology. 1999;265:178–84.PubMedGoogle Scholar
  455. 455.
    Centers for Disease Control and Prevention. Update on vaccine-derived polioviruses—worldwide, July 2009–March 2011. MMWR Morb Mortal Wkly Rep. 2011;60:846–50.Google Scholar
  456. 456.
    Liang X, Zhang Y, Xu W, et al. An outbreak of poliomyelitis caused by type 1 vaccine-derived poliovirus in China. J Infect Dis. 2006;194:545–51.PubMedGoogle Scholar
  457. 457.
    Centers for Disease Control and Prevention. Update on vaccine-derived polioviruses—worldwide, January 2006–August 2007. MMWR Morb Mortal Wkly Rep. 2007;56:996–1001.Google Scholar
  458. 458.
    Centers for Disease Control and Prevention. Update on vaccine-derived polioviruses—worldwide, January 2008–June 2009. MMWR Morb Mortal Wkly Rep. 2009;58:1002–6.Google Scholar
  459. 459.
    Rakoto-Andrianarivelo M, Gumede N, Jegouic S, et al. Reemergence of recombinant vaccine-derived poliovirus outbreak in Madagascar. J Infect Dis. 2008;197:1427–35.PubMedGoogle Scholar
  460. 460.
    Centers for Disease Control and Prevention. Update on vaccine-derived polioviruses—worldwide, July 2012–December 2013. Morbid Mortal Wkly Rep. 2014;63:242–8.Google Scholar
  461. 461.
    Wringe A, Fine PEM, Sutter RW, Kew OM. Estimating the extent of vaccine-derived poliovirus infection. PLoS One. 2008;3:e3433.PubMedPubMedCentralGoogle Scholar
  462. 462.
    Yoneyama T, Hagiwara A, Hara M, Shimojo H. Alteration in oligonucleotide fingerprint patterns of the viral genome in poliovirus type 2 isolated from paralytic patients. Infect Immun. 1982;37:46–53.PubMedPubMedCentralGoogle Scholar
  463. 463.
    Minor P. Characteristics of poliovirus strains from long-term excretors with primary immunodeficiencies. Dev Biol (Basel). 2001;105:75–80.Google Scholar
  464. 464.
    Martín J. Vaccine-derived poliovirus from long term excretors and the end game of polio eradication. Biologicals. 2006;34:117–22.PubMedGoogle Scholar
  465. 465.
    MacCallum FO. Hypogammglobulinaemia in the United Kingdom. VII. The role of humoral antibodies in protection against and recovery from bacterial and virus infections in hypogammaglobulinaemia. Medical Research Council Special Report Series. 1971;310:72–85.Google Scholar
  466. 466.
    Labadie K, Pelletier I, Saulnier A, Martin J, Colbere-Garapin F. Poliovirus mutants excreted by a chronically infected hypogammaglobulinemic patient establish persistent infections in human intestinal cells. Virology. 2004;318:66–78.PubMedGoogle Scholar
  467. 467.
    Centers for Disease Control and Prevention. Update on vaccine-derived polioviruses. MMWR Morb Mortal Wkly Rep. 2006;55:1093–7.Google Scholar
  468. 468.
    Misbah SA, Lawrence PA, Kurtz JB, Chapel HM. Prolonged faecal excretion of poliovirus in a nurse with common variable hypogammaglobulinaemia. Postgrad Med J. 1991;67:301–3.PubMedPubMedCentralGoogle Scholar
  469. 469.
    Shahmahmoodi S, Mamishi S, Aghamohammadi A, et al. Vaccine-associated paralytic poliomyelitis in immunodeficient children, Iran, 1995-2008. Emerg Infect Dis. 2010;16:1133–6.PubMedPubMedCentralGoogle Scholar
  470. 470.
    Hidalgo S, Garcia Erro M, Cisterna D, Freire MC. Paralytic poliomyelitis caused by a vaccine-derived polio virus in an antibody-deficient Argentinean child. Pediatr Infect Dis J. 2003;22:570–2.PubMedGoogle Scholar
  471. 471.
    Centers for Disease Control and Prevention. Laboratory surveillance for wild and vaccine-derived polioviruses, January 2003–June 2004. MMWR Morb Mortal Wkly Rep. 2004;53:990–3.Google Scholar
  472. 472.
    Tharmaphornpilas P. Vaccine-derived poliovirus, Thailand, 2003. Emerg Infect Dis. 2005;11:777–8.PubMedPubMedCentralGoogle Scholar
  473. 473.
    Parvaneh N, Shahmahmoudi S, Tabatabai H, et al. Vaccine-associated paralytic poliomyelitis in a patient with MHC class II deficiency. J Clin Virol. 2007;39:145–8.PubMedGoogle Scholar
  474. 474.
    de Silva R, Gunasena S, Ratnayake D, et al. Prevalence of prolonged and chronic poliovirus excretion among persons with primary immune deficiency disorders in Sri Lanka. Vaccine. 2012;30:7561–5.PubMedGoogle Scholar
  475. 475.
    Gumede N, Muthambi V, Schoub BD. Immunodeficiency-associated vaccine-derived poliovirus type 3 in infant, South Africa, 2011. Emerg Infect Dis. 2012;18:992–4.PubMedPubMedCentralGoogle Scholar
  476. 476.
    Yong PFK, Thaventhiran JED, Grimbacher B. “A rose is a rose is a rose,” but CVID is Not CVID common variable immune deficiency (CVID), what do we know in 2011? Adv Immunol. 2011;111:47–107.PubMedGoogle Scholar
  477. 477.
    Oberste MS, Moore D, Anderson B, Pallansch MA, Pevear DC, Collett MS. In vitro antiviral activity of V-073 against polioviruses. Antimicrob Agents Chemother. 2009;53:4501–3.PubMedPubMedCentralGoogle Scholar
  478. 478.
    Adu FD, Iber J, Bukbuk D, et al. Isolation of recombinant type 2 vaccine-derived poliovirus (VDPV) from a Nigerian child. Virus Res. 2007;127:17–25.PubMedGoogle Scholar
  479. 479.
    Centers for Disease Control and Prevention. Laboratory surveillance for wild and vaccine-derived polioviruses, January 2002–June 2003. MMWR Morb Mortal Wkly Rep. 2003;52:913–6.Google Scholar
  480. 480.
    Roivainen M, Blomqvist S, Al-Hello H, et al. Highly divergent neurovirulent vaccine-derived polioviruses of all three serotypes are recurrently detected in Finnish sewage. Euro Surv. 2010; 15:pii/19566.Google Scholar
  481. 481.
    Smith J, Leke R, Adams A, Tangermann RH. Certification of polio eradication: process and lessons learned. Bull World Health Organ. 2004;82:24–30.PubMedPubMedCentralGoogle Scholar
  482. 482.
    Breman JG, Arita I. The confirmation and maintenance of smallpox eradication. N Engl J Med. 1980;303:1263–73.PubMedGoogle Scholar
  483. 483.
    Chiba Y, Murakami H, Kobayashi M, et al. A case of poliomyelitis associated with infection of wild poliovirus in Qinghai Province, China, in October 1999. Jpn J Infect Dis. 2000;53:135–6.PubMedGoogle Scholar
  484. 484.
    World Health Organization. Wild poliovirus imported into Qinghai province, China. Wkly Epidemiol Rec. 2000;75:55–7.Google Scholar
  485. 485.
    Kojouharova M, Zuber PLF, Gyurova S, et al. Importation and circulation of poliovirus in Bulgaria in 2001. Bull World Health Organ. 2003;81:476–81.PubMedPubMedCentralGoogle Scholar
  486. 486.
    World Health Organization. Certification of poliomyelitis eradication: Western Pacific Region. Wkly Epidemiol Rec. 2000;75:399–400.Google Scholar
  487. 487.
    World Health Organization. Global action plan for laboratory containment of wild polioviruses, 2nd ed. Geneva: World Health Organization; 2003. Report No.: WHO/V&B/03.11.Google Scholar
  488. 488.
    Dowdle WR, Wolff C, Sanders R, Lambert S, Best M. Will containment of wild poliovirus in laboratories and inactivated poliovirus vaccine production sites be effective for global certification? Bull World Health Organ. 2004;82:59–62.PubMedPubMedCentralGoogle Scholar
  489. 489.
    Centers for Disease Control and Prevention. National laboratory inventory for global poliovirus containment—United States, November 2003. MMWR Morb Mortal Wkly Rep. 2004;53:457–9.Google Scholar
  490. 490.
    World Health Organization. Completion of national laboratory inventories for wild poliovirus containment—WHO Western Pacific Region, December 2008. Wkly Epidemiol Rec. 2009;84:373–82.Google Scholar
  491. 491.
    Anis E, Kopel E, Singer SR, et al. Insidious reintroduction of wild poliovirus into Israel, 2013. Eurosurveillance. 2013;18:1–5.Google Scholar
  492. 492.
    Resik S, Tejeda A, Más Lago P, et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba. J Infect Dis. 2010;201:1344–52.PubMedGoogle Scholar
  493. 493.
    Tano Y, Shimizu H, Martin J, Nishimura Y, Simizu B, Miyamura T. Antigenic characterization of a formalin-inactivated poliovirus vaccine derived from live-attenuated Sabin strains. Vaccine. 2007;25:7041–6.PubMedGoogle Scholar
  494. 494.
    Verdijk P, Rots NY, Bakker WA. Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strains. Expert Rev Vaccines. 2011;10:635–44.PubMedGoogle Scholar
  495. 495.
    Liao G, Li R, Li C, et al. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: a phase II, randomized, positive-controlled trial. J Infect Dis. 2012;205:237–43.PubMedGoogle Scholar
  496. 496.
    Burns CC, Shaw J, Campagnoli R, et al. Modulation of poliovirus replicative fitness in HeLa cells by deoptimization of synonymous codon usage in the capsid region. J Virol. 2006;80:3259–72.PubMedPubMedCentralGoogle Scholar
  497. 497.
    Macadam AJ, Ferguson G, Stone DM, et al. Rational design of genetically stable, live-attenuated poliovirus vaccines of all three serotypes: relevance to poliomyelitis eradication. J Virol. 2006;80:8653–63.PubMedPubMedCentralGoogle Scholar
  498. 498.
    Mueller S, Papamichail D, Coleman JR, Skiena S, Wimmer E. Reduction of the rate of poliovirus protein synthesis through large-scale codon deoptimization causes attenuation of viral virulence by lowering specific infectivity. J Virol. 2006;80:9687–96.PubMedPubMedCentralGoogle Scholar
  499. 499.
    Vignuzzi M, Wendt E, Andino R. Engineering attenuated virus vaccines by controlling replication fidelity. Nat Med. 2008;14:154–61.PubMedGoogle Scholar
  500. 500.
    Thompson KM, Pallansch MA, Duintjer Tebbens RJ, Wassilak SG, Kim JH, Cochi SL. Preeradication vaccine policy options for poliovirus infection and disease control. Risk Anal. 2013;33:516–43.PubMedGoogle Scholar
  501. 501.
    World Health Organization. Global Invasive Bacterial Vaccine Preventable Diseases (IB-VPD). Information and Surveillance Bulletin. 2013.Google Scholar
  502. 502.
    World Health Organization. Progress in introduction of pneumococcal conjugate vaccine worldwide, 2000–2012. Wkly Epidemiol Rec. 2013;88:173–80.Google Scholar
  503. 503.
    World Health Organization. Meningococcal disease in countries of the African meningitis belt, 2012—emerging needs and future perspectives. Wkly Epidemiol Rec. 2013;88:129–36.Google Scholar
  504. 504.
    MacCallum FO. Hypogammaglobulinaemia in the United Kingdom. VII. The role of humoral antibodies in the protection against and recovery from bacterial and virus infections in hypogammaglobulinaemia. Spec Rep Ser Med Res Counc (G B). 1971;310:72–85.Google Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Polio and Picornavirus Laboratory Branch, Division of Viral DiseasesNational Center for Immunization and Respiratory Diseases, Centers for Disease Control and PreventionAtlantaUSA

Personalised recommendations